#### **PCT**

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



#### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:		(11) International Publication Number:	WO 95/10618
C12N 15/60, 9/00, 9/88	A2	(43) International Publication Date:	20 April 1995 (20.04.95
<ul> <li>(21) International Application Number: PCT/ER</li> <li>(22) International Filing Date: 15 October 1994 (20)</li> <li>(30) Priority Data: 9321301.5 15 October 1993 (15.10.93)</li> <li>(71) Applicant (for all designated States except US): In A/S [DK/DK]; Langebrogade 1, P.O. Box 17, Copenhagen K (DK).</li> <li>(72) Inventors; and Gunnar Hejdemans Gata 29, S-212 40 Malmo (100.00) JSEN, Kirsten [DK/DK]; Hvidehusvej 13, DK-345 (DK). KRAGH, Karsten, Matthias [DK/DK]; 139 A, DK-8260 Viby J (DK). BOJKO, Maja Frugtparken 11, DK-2820 Gentofte (DK). NIELS [DK/DK]; Engvej 38, DK-2300 Copenhagen S (DI CUSSEN, Jan [DK/DK]; Knabrostraede 25, 2., Copenhagen K (DK).</li> <li>(74) Agent: HARDING, Charles, Thomas; D. Young &amp; New Fetter Lane, London EC4A 1DA (GB).</li> </ul>	CN/SE SE). BC OANISC (CN/SE SE). BC OANISC (CN/SE SE). BC OANISC (CN/DK) CN/DK SEN, John K). MAI DK-121	CN, CZ, DE, DK, ES, FI, GB KR, KZ, LK, LT, LU, LV, M NZ, PL, PT, RO, RU, SD, SE UZ, VN, European patent (AT GB, GR, IE, IT, LU, MC, NL, BJ, CF, CG, CI, CM, GA, GN, ARIPO patent (KE, MW, SD, SE)  Published Without international search re upon receipt of that report.	, GE, HU, JP, KE, KG, KF D, MG, MN, MW, NL, NO 3, SI, SK, TJ, TT, UA, US 4, BE, CH, DE, DK, ES, FR 5, PT, SE), OAPI patent (BF ML, MR, NE, SN, TD, TG) SZ).

(54) Title: ALPHA-1,4-GLUCAN LYASE FROM A FUNGUS INFECTED ALGAE, ITS PURIFICATION, GENE CLONING AND EXPRESSION IN MICROORGANISMS

#### (57) Abstract

A method of preparing  $\alpha$ -1,4-glucan lyase enzymes is described. The method comprises isolating the enzymes from a fungally infected algae. The amino acid sequences of the enzymes have been determined. The nucleic acid sequences coding for the enzymes have also been determined.

#### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	rr	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic	SD	Sudan
CG	Congo		of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SI	Slovenia
CI	Côte d'Ivoire	KZ	Kazakhstan	SK	Slovakia
CM	Cameroon	LI	Liechtenstein	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
cz	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	MIL	Mali	UZ	Uzbekistan
FR	Prance	MN	Mongolia	VN	Viet Nam
GA	Gabon				

## ALPHA-1,4-GLUCAN LYASE FROM A FUNGUS INFECTED ALGAE, ITS PURIFICATION, GENE CLONING AND EXPRESSION IN MICROORGANISMS

The present invention relates to an enzyme, in particular  $\alpha$ -1,4-glucan lyase ("GL"). The present invention also relates to a method of extracting the same. The present invention also relates to nucleotide sequence(s) encoding for the same.

5

10

25

FR-A-2617502 and Baute et al in Phytochemistry [1988] vol. 27 No.11 pp3401-3403 report on the production of 1,5-D-anhydrofructose ("AF") in *Morchella vulgaris* by an apparent enzymatic reaction. The yield of production of AF is quite low. Despite a reference to a possible enymatic reaction, neither of these two documents presents any amino acid sequence data for any enzyme, let alone any nucleotide sequence information. These documents say that AF can be a precursor for the preparation of the antibiotic pyrone microthecin.

Yu et al in Biochimica et Biophysica Acta [1993] vol 1156 pp313-320 report on the preparation of GL from red seaweed and its use to degrade α-1,4-glucan to produce AF. The yield of production of AF is quite low. Despite a reference to the enzyme GL this document does not present any amino acid sequence data for that enzyme let alone any nucleotide sequence information coding for the same. This document also suggests that the source of GL is just algal.

According to the present invention there is provided a method of preparing the enzyme  $\alpha$ -1,4-glucan lyase comprising isolating the enzyme from a fungally infected algae.

Preferably the enzyme is isolated and/or further purified using a gel that is not degraded by the enzyme.

Preferably the gel is based on dextrin, preferably beta-cyclodextrin, or derivatives thereof, preferably a cyclodextrin, more preferably beta-cyclo-dextrin.

According to the present invention there is also provided a GL enzyme prepared by the method of the present invention.

Preferably the enzyme comprises the amino acid sequence SEQ. ID. No. 1. or SEQ. ID. No. 2, or any variant thereof.

The term "any variant thereof" means any substitution of, variation of, modification of, replacement of, deletion of or addition of at least one amino acid from or to the sequence providing the resultant enzyme has lyase activity.

10

5

According to the present invention there is also provided a nucleotide sequence coding for the enzyme  $\alpha$ -1,4-glucan lyase, preferably wherein the sequence is not in its natural environment (i.e. does not form part of the natural genome of a cellular organism expressing the enzyme).

15

20

25

30

Preferably the nucleotide sequence is a DNA sequence.

Preferably the DNA sequence comprises a sequence that is the same as, or is complementary to, or has substantial homology with, or contains any suitable codon substitution(s) for any of those of, SEQ. ID. No. 3 or SEQ. ID. No. 4.

The expression "substantial homology" covers homology with respect to structure and/or nucleotide components and/or biological activity.

The expression "contains any suitable codon substitutions" covers any codon replacement or substitution with another codon coding for the same amino acid or any addition or removal thereof providing the resultant enzyme has lyase activity.

In other words, the present invention also covers a modified DNA sequence in which at least one nucleotide has been deleted, substituted or modified or in which at least one additional nucleotide has been inserted so as to encode a polypeptide having the activity of a glucan lyase, preferably an enzyme having an increased lyase activity.

3

According to the present invention there is also provided a method of preparing the enzyme  $\alpha$ -1,4-glucan lyase comprising expressing the nucleotide sequence of the present invention.

According to the present invention there is also provided the use of beta-cyclodextrin to purify an enzyme, preferably GL.

According to the present invention there is also provided a nucleotide sequence wherein the DNA sequence comprises a sequence that is the same as, or is complementary to, or has substantial homology with, or contains any suitable codon substitutions for any of those of, SEQ. ID. No. 3 or SEQ. ID. No. 4, preferably wherein the sequence is in isolated form.

10

15

20

25

30

A key aspect of the present invention is the recognition that GL is derived from a fungally infected algae. This is the first time that the amino acid sequence of GL has been determined in addition to the determination of the nucleic acid sequences that code for GL. A key advantage of the present invention is therefore that GL can now be made in large quantities by for example recombinant DNA techniques and thus enable compounds such as the antibiotic microthecin to be made easily and in larger amounts.

The enzyme should preferably be secreted to ease its purification. To do so the DNA encoding the mature enzyme is fused to a signal sequence, a promoter and a terminator from the chosen host.

For expression in Aspergillus niger the gpdA (from the Glyceraldehyde-3-phosphate dehydrogenase gene of Aspergillus nidulans) promoter and signal sequence is fused to the 5' end of the DNA encoding the mature lyase - such as SEQ I.D. No. 3 or SEQ. I.D. No.4. The terminator sequence from the A. niger trpC gene is placed 3'

SEQ. I.D. No.4. The terminator sequence from the A. niger trpC gene is placed 3' to the gene (Punt, P.J. et al (1991): J. Biotech. 17, 19-34). This construction is inserted into a vector containing a replication origin and selection origin for E. coli and a selection marker for A. niger. Examples of selection markers for A. niger are

4

the amdS gene, the argB gene, the pyrG gene, the hygB gene, the BmlR gene which all have been used for selection of transformants. This plasmid can be transformed into A. niger and the mature lyase can be recovered from the culture medium of the transformants.

5

15

20

The construction can be transformed into a protease deficient strain to reduce the proteolytic degradation of the lyase in the culture medium (Archer D.B. et al (1992): Biotechnol. Lett. 14, 357-362).

10 Other advantages will become apparent in the light of the following description.

The present invention therefore relates to the isolation of the enzyme  $\alpha$ -1,4-glucan lyase from a fungus infected algae - preferably a fungus infected red algae such as the type that can be collected in China - such as *Gracilariopsis lemaneiformis*. An example of a fungally infected algae has been deposited in accordance with the Budapest Treaty (see below).

By using in situ hybridisation technique it was established that the enzyme GL was detected in the fungally infected red algae Gracilariopsis lemaneiformis. Further evidence that supports this observation was provided by the results of Southern hybridisation experiments. Thus GL enzyme activity can be obtained from fungally infected algae, rather than just from the algae as was originally thought.

Of particular interest is the finding that there are two natural DNA sequences, each of which codes for an enzyme having GL characteristics. These DNA nucleic acid sequences have been sequenced and they are presented as SEQ. I.D. No. 3 and SEQ. I.D. No. 4 (which are discussed and presented later).

30

25

An initial enzyme purification can be performed by the method as described by Yu et al (ibid). However, it is preferred that the initial enzyme purification includes the use of a solid support that does not decompose under the purification step. This gel support has the advantage that it is compatible with standard laboratory protein

5

purification equipment. The details of this preferred purification process are given later on. The purification is terminated by known standard techniques for protein purification. The purity of the enzyme was established using complementary electroforetic techniques.

5

The purified lyase was characterized according to pI, temperature- and pH-optima. In this regard, it was found that the enzyme has the following characteristics: an optimium substrate specificity and a pH optimum at 3.5-7.5 when amylopectin is used; a temperature optimum at 50°C and a pI of 3.9

10

As mentioned above, the enzymes according to the present invention have been determined (partially by amino-acid sequencing techniques) and their amino acid sequences are provided later. Likewise the nucleotide sequences coding for the enzymes according to the present invention (i.e. GL) have been sequenced and the DNA sequences are provided later.

15

The following samples were deposited in accordance with the Budapest Treaty at the recognised depositary The National Collections of Industrial and Marine Bacteria Limited (NCIMB) at 23 St. Machar Drive, Aberdeen, Scotland, United Kingdom, AB2 1RY on 20 June 1994:

20

E. Coli containing plasmid pGL1 (NCIMB 40652) - [ref. DH5alpha-pGL1]; and

E. Coli containing plasmid pGL2 (NCIMB 40653) - [ref. DH5alpha-pGL2].

25

The following sample was accepted as a deposit in accordance with the Budapest Treaty at the recognised depositary The Culture Collection of Algae and Protozoa (CCAP) at Dunstaffnage Marine Laboratory PO Box 3, Oban, Argyll, Scotland, United Kingdom, PA34 4AD on 11 October 1994:

30

Fungally infected *Gracilariopsis lemaneiformis* (CCAP 1373/1) - [ref. GLQ-1 (Qingdao)].

Thus highly preferred embodiments of the present invention include a GL enzyme obtainable from the expression of the GL coding sequences present in plasmids that are the subject of either deposit NCIMB 40652 or deposit NCIMB 40653; and a GL enzyme obtainable from the fungally infected algae that is the subject of deposit CCAP 1373/1.

The present invention will now be described only by way of example.

In the following Examples reference is made to the accompanying figures in which:

10

5

WO 95/10618

Figure 1 shows stained fungally infected algae;

Figure 2 shows stained fungally infected algae;

Figure 3 shows sections of fungal hypha;

Figure 4 shows sections of fungally infected algae;

Figure 5 shows a section of fungally infected algae;

20

Figure 6 shows a plasmid map of pGL1;

Figure 7 shows a plasmid map of pGL2;

Figure 8 shows the amino acid sequence represented as SEQ. I.D. No.3 showing positions of the peptide fragments that were sequenced;

Figure 9 shows the alignment of SEQ. I.D. No. 1 with SEQ. I.D. No.2;

Figure 10 is a microphotograph.

WO 95/10618

In more detail, Figure 1 shows Calcoflour White stainings revealing fungi in upper part and lower part of *Gracilariopsis lemaneiformis* (108x and 294x).

Figure 2 shows PAS/Anilinblue Black staining of *Gracilariopsis lemaneiformis* with fungi. The fungi have a significant higher content of carbohydrates.

Figure 3 shows a micrograph showing longitudinal and grazing sections of two thin-walled fungal hypha (f) growing between thick walls (w) of algal cells. Note thylacoid membranes in the algal chloroplast (arrows).

10

20

25

30

Figure 4 shows the antisense detections with clone 2 probe (upper row) appear to be restricted to the fungi illustrated by Calcoflour White staining of the succeeding section (lower row) (46x and 108x).

Figure 5 shows intense antisense detections with clone 2 probe are found over the fungi in *Gracilariopsis lemaneiformis* (294x).

Figure 6 shows a map of plasmid pGL1 - which is a pBluescript II KS containing a 3.8 kb fragment isolated from a genomic library constructed from fungal infected *Gracilariopsis lemaneiformis*. The fragment contains a gene coding for alpha-1,4-glucan lyase.

Figure 7 shows a map of plasmid pGL2 - which is a pBluescript II SK containing a 3.6 kb fragment isolated from a genomic library constructed from fungal infected *Gracilariopsis lemaneiformis*. The fragment contains a gene coding for alpha-1,4-glucan lyase.

Figure 9 shows the alignment of SEQ. I.D. No. 1 (GL1) with SEQ. I.D. No. 2 (GL2). The total number of residues for GL1 is 1088; and the total number of residues for GL2 is 1091. In making the comparison, a structure-genetic matrix was used (Open gap cost: 10; Unit gap cost: 2). In Figure 9 the character to show that two aligned residues are identical is ':'; and the character to show that two aligned

8

residues are similar is '.'. Amino acids said to be 'similar' are: A,S,T; D,E; N,Q; R,K; I,L,M,V; F,Y,W. Overall there is an identity of 845 amino acids (i.e. 77.67%); a similarity of 60 amino acids (5.51%). The number of gaps inserted in GL1 are 3 and the number of gaps inserted in GL2 are 2.

5

Figure 10 is a microphotograph of a fungal hypha (f) growing between the algal walls (w). Note grains of floridean starch (s) and thylakoids (arrows) in the algal cell.

The following sequence information was used to generate primers for the PCR reactions mentioned below and to check the amino acid sequence generated by the respective nucleotide sequences.

Amino acid sequence assembled from peptides from fungus infected Gracilariopsis lemaneiformis

15

20

Tyr Arg Trp Gln Glu Val Leu Tyr Thr Ala Met Tyr Gln Asn Ala Ala Phe Gly Lys Pro Ile Ile Lys Ala Ala Ser Met Tyr Asn Asn Asp Ser Asn Val Arg Arg Ala Gln Asn Asp His Phe Leu Leu Gly Gly His Asp Gly Tyr Arg Ile Leu Cys Ala Pro Val Val Trp Glu Asn Ser Thr Glu Arg Glu Leu Tyr Leu Pro Val Leu Thr Gln Trp Tyr Lys Phe Gly Pro Asp Phe Asp Thr Lys Pro Leu Glu Gly Ala

The Amino acid sequence (27-34) used to generate primer A and B (Met Tyr Asn Asn Asp Ser Asn Val)

25

Primer A

ATG TA(TC) AA(CT) AA(CT) GA(CT) TC(GATC) AA(CT) GT 128 mix

Primer B

30 ATG TA(TC) AA(CT) AA(CT) GA(CT) AG(CT) AA(CT) GT 64 mix

9

The Amino acid sequence (45-50) used to generate primer C (Gly Gly His Asp Gly Tyr)

Primer C

5 TA (GATC)CC (GA)TC (GA)TG (GATC)CC (GATC)CC 256 mix [The sequence corresponds to the complementary strand.]

The Amino acid sequence (74-79) used to generate primer E (Gln Trp Tyr Lys Phe Gly)

10

Primer E

GG(GATC) CC(GA) AA(CT) TT(GA) TAC CA(CT) TG 64 mix [The sequence corresponds to the complementary strand.]

The Amino acid sequence (1-6) used to generate primer F1 and F2 (Tyr Arg Trp Gln Glu Val)

Primer F1

TA(TC) CG(GATC) TGG CA(GA) GA(GA) GT 32 mix

20

Primer F2

TA(TC) AG(GA) TGG CA(GA) GA(GA) GT 16 mix

The sequence obtained from the first PCR amplification (clone 1)

25

ATGTACAÁCA ACGACTCGAA CGTTCGCAGG GCGCAGAACG ATCATTTCCT
TCTTGGCGGC CACGACGGTT A

Met Tyr Asn Asn Asp Ser Asn Val Arg Arg Ala Gln Asn Asp His Phe Leu Leu Gly
Gly His Asp Gly

10

The sequence obtained from the second PCR amplification (clone 1)

ATGTACAACA ACGACTCGAA CGTTCGCAGG GCGCAGAACG ATCATTTCCT

TCTTGGTGGA CATGATGGAT ATCGCATTCT GTGCGCGCCT GTTGTGTGGG

AGAATTCGAC CGAACGNGAA TTGTACTTGC CCGTGCTGAC CCAATGGTAC

5 AAATTCGGCC C

Met Tyr Asn Asn Asp Ser Asn Val Arg Arg Ala Gln Asn Asp His Phe Leu Leu Gly Gly His Asp Gly Tyr Arg Ile Leu Cys Ala Pro Val Val Trp Glu Asn Ser Thr Glu Arg Glu Leu Tyr Leu Pro Val Leu Thr Gln Trp Tyr Lys Phe Gly Pro

10

The sequence obtained from the third PCR amplification (clone2)

TACAGGTGGC AGGAGGTGTT GTACACTGCT ATGTACCAGA
ATGCGGCTTT CGGGAAACCG ATTATCAAGG CAGCTTCCAT

GTACGACAAC GACAGAAACG TTCGCGGCGC ACAGGATGAC
CACTTCCTTC TCGGCGGACA CGATGGATAT CGTATTTTGT
GTGCACCTGT TGTGTGGGAG AATACAACCA GTCGCGATCT
GTACTTGCCT GTGCTGACCA GTGGTACAAA TTCGGCCC

Tyr Arg Trp Gln Glu Val Leu Tyr Thr Ala Met Tyr Gln Asn Ala Ala Phe Gly Lys
Pro Ile Ile Lys Ala Ala Ser Met Tyr Asp Asn Asp Arg Asn Val Arg Gly Ala Gln Asp
Asp His Phe Leu Leu Gly Gly His Asp Gly Tyr Arg Ile Leu Cys Ala Pro Val Val
Trp Glu Asn Thr Thr Ser Arg Asp Leu Tyr Leu Pro Val Leu Thr Lys Trp Tyr Lys
Phe Gly

25

11

## 1. CYTOLOGICAL INVESTIGATIONS OF GRACILARIOPSIS LEMANEIFORMIS

#### 1.1.1 Detection of fungal infection in Gracilariopsis lemaneiformis

5

Sections of *Gracilariopsis lemaneiformis* collected in China were either hand cut or cut from paraffin embedded material. Sectioned material was carefully investigated by light microscopy. Fungal hyphae were clearly detected in *Gracilariopsis lemaneiformis*.

10

15

The thalli of the *Gracilariopsis lemaneiformis* are composed of cells appearing in a highly ordered and almost symmetric manner. The tubular thallus of G. lemaneiformis is composed of large, colourless central cells surrounded by elongated, slender, ellyptical cells and small, round, red pigmented peripherial cells. All algal cell types are characterized by thick cell walls. Most of the fungal hyphae are found at the interphase between the central layer of large cells and the peripherial layer. These cells can clearly be distinguished from the algae cells as they are long and cylindrical. The growth of the hyphae is observed as irregularities between the highly ordered algae cells. The most frequent orientation of the hypha is along the main axis of the algal thallus. Side branches toward the central and periphery are detected in some cases. The hypha can not be confused with the endo/epiphytic 2nd generation of the algae.

20

25

Calcofluor White is known to stain chitin and cellulose containing tissue. The reaction with chitin requires four covalently linked terminal n-acetyl glucosamine residues. It is generally accepted that cellulose is almost restricted to higher plants although it might occur in trace amounts in some algae. It is further known that chitin is absent in *Gracilaria*.

30

Calcofluor White was found to stain domains corresponding to fungi hyfa cell walls in sectioned *Gracilariopsis lemaneiformis* material.

12

The hypha appear clear white against a faint blue background of *Gracilaria* tissue when observed under u.v. light - see Figure 1. Chitin is the major cell wall component in most fungi but absent in *Gracilaria*. Based upon these observations we conclude that the investigated algae is infected by a fungi. 40% of the lower parts of the investigated *Gracilariopsis lemaneiformis* sections were found to be infected with fungal hyphae. In the algae tips 25% of the investigated *Gracilariopsis lemaneiformis* sections were found to be infected.

Staining of sectioned *Gracilariopsis lemaneiformis* with Periodic acid Schiff (PAS) and Aniline blue black revealed a significantly higher content of carbohydrates within the fungal cells as compared with the algae cells - see Figure 2. Safranin O and Malachit Green showed the same colour reaction of fungi cells as found in higher plants infected with fungi.

An Acridin Orange reaction with sectioned *Gracilariopsis lemaneiformis* showed clearly the irregularly growth of the fungus.

#### 1.1.2 Electron Microscopy

5

10

30

Slides with 15 μm thick sections, where the fungus was detected with Calcofluor White were fixed in 2% OsO<sub>4</sub>, washed in water and dehydrated in dimethoxypropane and absolute alcohol. A drop of a 1:1 mixture of acetone and Spurr resin was placed over each section on the glass slide, and after one hour replaced by a drop of pure resin. A gelatin embedding capsule filled with resin was placed face down over the section and left over night at 4°C. After the polymerization at 55°C for 8 hrs, the thick sections adhering to the resin blocks could can be separated from the slide by immersion in liquid nitrogen.

Blocks were trimmed and 100 nm thick sections were cut using a diamond knife on a microtome. The sections were stained in aqueous uranyl acetate and in lead citrate. The sections were examined in an electron microscope at 80 kV.

The investigation confirmed the light microscopical observations and provided further evidence that the lyase producing, chinese strain of *G. lamneiformis* is infected by a fungal parasite or symbiont.

- Fungal hyphae are build of tubular cells 50 to 100 μm long and only few microns in diameter. The cells are serially arranged with septate walls between the adjacent cells. Ocasional branches are also seen. The hyphae grow between the thick cell walls of algal thallus without penetrating the wall or damaging the cell. Such a symbiotic association, called mycophycobiosis, is known to occur between some filamentous marine fungi and large marine algae (Donk and Bruning, 1992 Ecology of aquatic fungi in and on algae. In Reisser, W.(ed.): Algae and Symbioses: Plants, Animals, Fungi, Viruses, Interactions Explored. Biopress Ltd., Bristol.)
- Examining the microphotograph in Figure 10, several differences between algal and fungal cells can be noticed. In contrast to several  $\mu$ m thick walls of the alga, the fungal walls are only 100-200 nm thick. Plant typical organells as chloroplasts with thyllacoid membranes as well as floridean starch grains can be seen in algal cells, but not in the fungus.
- Intercellular connections of red algae are characterized by specific structures termed pit plugs, or pit connections. The structures are prominent, electron dense cores and they are important features in algal taxonomy (Pueschel, C.M.: An expanded survey of the ultrastructure of Red algal pit plugs. J. Phycol. 25, 625, (1989)). In our material, such connections were frequently observed in the algal thallus, but never between the cells of the fungus.

#### 1.2 In situ Hybridization experiments

In situ hybridization technique is based upon the principle of hybridization of an antisense ribonucotide sequence to the mRNA. The technique is used to visualize areas in microscopic sections where said mRNA is present. In this particular case the technique is used to localize the enzyme  $\alpha$ -1,4-glucan lyase in sections of

14

Gracilariopsis lemaneiformis.

#### 1.2.1 Preparation of <sup>35</sup>S labelled probes for *In situ* hybridization

A 238 bp PCR fragment from a third PCR amplification - called clone 2 (see above) - was cloned into the pGEM-3Zf(+) Vector (Promega). The transcription of the antisense RNA was driven by the SP6 promotor, and the sense RNA by the T7 promotor. The Ribonuclease protection assay kit (Ambion) was used with the following modifications. The transcripts were run on a 6% sequencing gel to remove the unincorporated nucleotide and eluted with the elution buffer supplied with the T7RNA polymerase in vitro Transcription Kit (Ambion). The antisense transcript contained 23 non-coding nucleotides while the sense contained 39. For hybridization 107 cpm/ml of the 35S labelled probe was used.

In situ hybridisation was performed essentially as described by Langedale et.al.(1988). The hybridization temperature was found to be optimal at 45°C. After washing at 45°C the sections were covered with KodaK K-5 photographic emulsion and left for 3 days at 5°C in dark (Ref: Langedale, J.A., Rothermel, B.A. and Nelson, T. (1988). Genes and development 2: 106-115. Cold Spring Harbour Laboratory).

The *in situ* hybridization experiments with riboprobes against the mRNA of  $\alpha$ -1,4-glucan lyase, show strong hybridizations over and around the hypha of the fungus detected in *Gracilariopsis lemaneiformis* - see Figures 4 and 5. This is considered a strong indication that the  $\alpha$ -1,4-glucan lyase is produced. A weak random background reactions were detected in the algae tissue of both *Gracilariopsis lemaneiformis*. This reaction was observed both with the sense and the antisense probes. Intense staining over the fungi hypha was only obtained with antisense probes.

30

25

5

10

15

20

These results were obtained with standard hybridisation conditions at 45°C in hybridization and washing steps. At 50°C no staining over the fungi was observed,

15

whereas the background staining remained the same. Raising the temperature to 55°C reduced the background staining with both sense and antisense probes significantly and equally.

Based upon the cytological investigations using complementary staining procedures it is concluded that *Gracilariopsis lemaneiformis* is fungus infected. The infections are most pronounced in the lower parts of the algal tissue.

In sectioned *Gracilariopsis lemaneiformis* material *in situ* hybridization results clearly indicate that hybridization is restricted to areas where fungal infections are found - see Figure 4. The results indicate that  $\alpha$ -1,4-glucan lyase mRNA appears to be restricted to fungus infected areas in *Gracilariopsis lemaneiformis*.

Based upon these observations we conclude that  $\alpha$ -1,4-glucan lyase activity is detected in fungally infected *Gracilariopsis lemaneiformis*.

#### 2. ENZYME PURIFICATION AND CHARACTERIZATION

Purification of  $\alpha$ -1,4-glucan lyase from fungal infected *Gracilariopsis lemaneiformis* material was performed as follows.

#### 2.1 Materials and Methods

The algae were harvested by filtration and washed with 0.9% NaCl. The cells were broken by homogenization followed by sonication on ice for 6x3 min in 50 mM citrate-NaOH pH 6.2 (Buffer A). Cell debris were removed by centrifugation at 25,000xg for 40 min. The supernatant obtained at this procedure was regarded as cell-free extract and was used for activity staining and Western blotting after separation on 8-25% gradient gels.

10

15

20

16

#### 2.2 Separation by $\beta$ -cyclodextrin Sepharose gel

The cell-free extract was applied directly to a  $\beta$ -cyclodextrin Sepharose gel 4B clolumn (  $2.6 \times 18$  cm) pre equilibrated with Buffer A. The column was washed with 3 volumes of Buffer A and 2 volumes of Buffer A containing 1 M NaCl.  $\alpha$ -1,4-glucan lyase was eluted with 2 % dextrins in Buffer A. Active fractions were pooled and the buffer changed to 20 mM Bis-tris propane-HCl (pH 7.0, Buffer B).

Active fractions were applied onto a Mono Q HR 5/5 column pre-equilibrated with Buffer B. The fungal lyase was eluted with Buffer B in a linear gradient of 0.3 M NaCl.

The lyase preparation obtained after  $\beta$ -cyclodextrin Sepharose chromatography was alternatively concentrated to 150  $\mu$ l and applied on a Superose 12 column operated under FPLC conditions.

- 2.3 Assay for  $\alpha$ -1,4-glucan lyase activity and conditions for determination of substrate specificity, pH and temperature optimum
- The reaction mixture for the assay of the α-1,4-glucan lyase activity contained 10 mg ml<sup>-1</sup> amylopectin and 25 mM Mes-NaOH (pH 6.0). The reaction was carried out at 30°C for 30 min and stopped by the addition of 3,5-dinitrosalicylic acid reagent. Optical density at 550nm was measured after standing at room temperature for 10 min.

15

5

17

## 3. AMINO ACID SEQUENCING OF THE $\alpha$ -1,4-GLUCAN LYASE FROM FUNGUS INFECTED GRACILARIOPSIS LEMANEIFORMIS

#### 3.1 Amino acid sequencing of the lyases

5

10

15

20

30

The lyases were digested with either endoproteinase Arg-C from Clostridium histolyticum or endoproteinase Lys-C from Lysobacter enzymogenes, both sequencing grade purchased from Boehringer Mannheim, Germany. For digestion with endoproteinase Arg-C, freeze dried lyase (0.1 mg) was dissolved in 50  $\mu$ l 10 M urea, 50 mM methylamine, 0.1 M Tris-HCl, pH 7.6. After overlay with N<sub>2</sub> and addition of 10  $\mu$ l of 50 mM DTT and 5 mM EDTA the protein was denatured and reduced for 10 min at 50°C under N<sub>2</sub>. Subsequently, 1  $\mu$ g of endoproteinase Arg-C in 10  $\mu$ l of 50 mM Tris-HCl, pH 8.0 was added, N<sub>2</sub> was overlayed and the digestion was carried out for 6h at 37°C. For subsequent cysteine derivatization, 12.5  $\mu$ l 100 mM iodoacetamide was added and the solution was incubated for 15 min at RT in the dark under N<sub>2</sub>.

For digestion with endoproteinase Lys-C, freeze dried lyase (0.1 mg) was dissolved in 50  $\mu$ l of 8 M urea, 0.4 M NH<sub>4</sub>HCO<sub>3</sub>, pH 8.4. After overlay with N<sub>2</sub> and addition of 5  $\mu$ l of 45 mM DTT, the protein was denatured and reduced for 15 min at 50°C under N<sub>2</sub>. After cooling to RT, 5  $\mu$ l of 100 mM iodoacetamide was added for the cysteines to be derivatized for 15 min at RT in the dark under N<sub>2</sub>.

Subsequently, 90  $\mu$ l of water and 5  $\mu$ g of endoproteinase Lys-C in 50  $\mu$ l of 50 mM tricine and 10 mM EDTA, pH 8.0, was added and the digestion was carried out for 24h at 37°C under N<sub>2</sub>.

The resulting peptides were separated by reversed phase HPLC on a VYDAC C18 column (0.46 x 15 cm; 10  $\mu$ m; The Separations Group; California) using solvent A: 0.1% TFA in water and solvent B: 0.1% TFA in acetonitrile. Selected peptides were rechromatographed on a Develosil C18 column (0.46 x 10 cm; 3  $\mu$ m; Dr. Ole Schou, Novo Nordisk, Denmark) using the same solvent system prior to sequencing on an

18

Applied Biosystems 476A sequencer using pulsed-liquid fast cycles.

The amino acid sequence information from the enzyme derived from fungus infected *Gracilariopsis lemaneiformis* is shown below, in particular SEQ. ID. No. 1. and SEQ. ID. No. 2.

SEO. I.D. No. 1 has:

Number of residues: 1088.

Amino acid composition (including the signal sequence)

10														
	61 Ala	15 Cys	19 His	34 Met	78 Thr									
	51 Arg	42 Gln	43 Ile	53 Phe	24 Trp									
	88 Asn	53 Glu	63 Leu	51 Pro	58 Tyr									
	79 Asp	100 Gly	37 Lys	62 Ser	77 Val									

15

30

5

#### SEO. I.D. No. 2 has:

Number of residues: 1091.

Amino acid composition (including the signal sequence)

20	58 Ala	16 Cys	14 His	34 Met	68 Thr
	57 Arg	40 Gln	44 Ile	56 Phe	23 Trp
	84 Asn	47 Glu	69 Leu	51 Pro	61 Tyr
	81 Asp	102 Gly	50 Lys	60 Ser	76 Val

#### 25 3.2 N-TERMINAL ANALYSIS

Studies showed that the N-terminal sequence of native glucan lyase 1 was blocked. Deblocking was achieved by treating glucan lyase 1 blotted onto a PVDF membrane with anhydrous TFA for 30 min at 40°C essentially as described by LeGendre et al. (1993) [Purification of proteins and peptides by SDS-PAGE; In: Matsudaira, P. (ed.) A practical guide to protein and peptide purification for microsequencing, 2nd edition; Academic Press Inc., San Diego; pp. 74-101.]. The sequence obtained was

19

TALSDKQTA, which matches the sequence (sequence position from 51 to 59 of SEQ. I.D. No.1) derived from the clone for glucan lyase 1 and indicates N-acetylthreonine as N-terminal residue of glucan lyase 1. Sequence position 1 to 50 of SEQ. I.D. No. 1 represents a signal sequence.

5

# 4. DNA SEQUENCING OF GENES CODING FOR THE α-1,4-GLUCAN LYASE FROM FUNGUS INFECTED GRACILARIOPSIS LEMANEIFORMIS

#### 4.1 METHODS FOR MOLECULAR BIOLOGY

10

15

DNA was isolated as described by Saunders (1993) with the following modification: The polysaccharides were removed from the DNA by ELUTIP-d (Schleicher & Schuell) purification instead of gel purification. (Ref:Saunders, G.W. (1993). Gel purification of red algal genomic DNA: An inexpensive and rapid method for the isolation of PCR-friendly DNA. Journal of phycology 29(2): 251-254 and Schleicher & Schuell: ELUTIP-d. Rapid Method for Purification and Concentration of DNA.)

#### 4.2 PCR

The preparation of the relevant DNA molecule was done by use of the Gene Amp DNA Amplification Kit (Perkin Elmer Cetus, USA) and in accordance with the manufactures instructions except that the Taq polymerase was added later (see PCR cycles) and the temperature cycling was changed to the following:

#### PCR cycles:

25	no of cycles	С	time (min.)
	1	98	5
		60	5
	addition of Tag po	olymerase and oil	
30	35	94	1
		47	. 2
		72	3
	1	72	20

20

#### 4.3 CLONING OF PCR FRAGMENTS

PCR fragments were cloned into pT7Blue (from Novagen) following the instructions of the supplier.

5

#### 4.4 DNA SEQUENCING

Double stranded DNA was sequenced essentially according to the dideoxy method of Sanger et al. (1979) using the Auto Read Sequencing Kit (Pharmacia) and the Pharmacia LKB A.L.F.DNA sequencer. (Ref: Sanger, F., Nicklen, S. and Coulson, A.R.(1979). DNA sequencing with chain-determinating inhibitors. Proc. Natl. Acad. Sci. USA 74: 5463-5467.).

The sequences are shown as SEQ. I.D.No.s 3 and 4, wherein

15

#### SEO. I.D. No. 3 has:

Total number of bases is: 3267.

DNA sequence composition: 850 A; 761 C; 871 G; 785 T

#### 20 <u>SEO. I.D. No. 4 has:</u>

Total number of bases is: 3276.

DNA sequence composition: 889 A; 702 C; 856 G; 829 T

#### 4.5 SCREENING OF THE LIBRARY

25

30

Screening of the Lambda Zap library obtained from Stratagene, was performed in accordance with the manufacturer's instructions except that the prehybridization and hybridization was performed in 2xSSC, 0.1% SDS, 10xDenhardt's and  $100\mu g/ml$  denatured salmon sperm DNA. To the hybridization solution a 32P-labeled denatured probe was added. Hybridization was performed over night at 55°C. The filters were washed twice in 2xSSC, 0.1% SDS and twice in 1xSSC, 0.1% SDS.

#### 4.6 PROBE

The cloned PCR fragments were isolated from the pT7 blue vector by digestion with appropriate restriction enzymes. The fragments were seperated from the vector by agarose gel electrophoresis and the fragments were purified from the agarose by Agarase (Boehringer Mannheim). As the fragments were only 90-240 bp long the isolated fragments were exposed to a ligation reaction before labelling with 32P-dCTP using either Prime-It random primer kit (Stratagene) or Ready to Go DNA labelling kit (Pharmacia).

10

20

25

30

5

#### 4.7 RESULTS

4.7.1 Generation of PCR DNA fragments coding for  $\alpha$ -1,4-glucan lyase.

15 The amino acid sequences of three overlapping tryptic peptides from  $\alpha$ -1,4-glucan lyase were used to generate mixed oligonucleotides, which could be used as PCR primers (see the sequences given above).

In the first PCR amplification primers A/B (see above) were used as upstream primers and primer C (see above) was used as downstream primer. The size of the expected PCR product was 71 base pairs.

In the second PCR amplification primers A/B were used as upstream primers and E was used as downstream primer. The size of the expected PCR product was 161 base pairs.

In the third PCR amplification primers F1 (see above) and F2 (see above) were used as upstream primers and E was used as downstream primer. The size of the expected PCR product was 238 base pairs. The PCR products were analysed on a 2% LMT agarose gel and fragments of the expected sizes were cut out from the gel and treated with Agarase (Boehringer Manheim) and cloned into the pT7blue Vector (Novagen) and sequenced.

The cloned fragments from the first and second PCR amplification coded for amino acids corresponding to the sequenced peptides (see above). The clone from the third amplification (see above) was only about 87% homologous to the sequenced peptides.

5 4.7.2 Screening of the genomic library with the cloned PCR fragments.

10

15

20

25

Screening of the library with the above-mentioned clones gave two clones. One clone contained the nucleotide sequence of SEQ I.D. No. 4 (gene 2). The other clone contained some of the sequence of SEQ I.D. No.3 (from base pair 1065 downwards) (gene 1).

The 5' end of SEQ. I.D. No. 3 (i.e. from base pair 1064 upwards) was obtained by the RACE (rapid amplification of cDNA ends) procedure (Michael, A.F., Michael, K.D. & Martin, G.R.(1988). Proc..Natl.Acad.Sci.USA 85:8998-99002.) using the 5' race system from Gibco BRL. Total RNA was isolated according to Collinge et al.(Collinge, D.B., Milligan D.E., Dow, J.M., Scofield, G.& Daniels, M.J.(1987). Plant Mol Biol 8: 405-414). The 5' race was done according to the protocol of the manufacturer, using  $1\mu g$  of total RNA. The PCR product from the second ammplification was cloned into pT7blue vector from Novagen according to the protocol of the manufacturer. Three independent PCR clones were sequenced to compensate for PCR errors.

An additional PCR was performed to supplement the clone just described with XbaI and NdeI restriction sites immediately in front of the ATG start codon using the following oligonucleotide as an upstream primer:

GCTCTAGAGCATGTTTTCAACCCTTGCG and a primer containing the complement sequence of bp 1573-1593 in sequence GLI (i.e. SEQ. I.D. No. 3) was used as a downstream primer.

The complete sequence for gene 1 (i.e. SEQ. I.D. No. 3) was generated by cloning the 3' end of the gene as a BamHI-HindIII fragment from the genomic clone into the pBluescript II KS+ vector from Stratagene and additionally cloning the PCR

generated 5' end of the gene as a Xbal-BamHI fragment in front of the 3' end.

Gene 2 was cloned as a HindIII blunt ended fragment into the EcoRV site of pBluescript II SK+ vector from Stratagene. A part of the 3' untranslated sequence was removed by a SacI digestion, followed by religation. HindIII and HpaI restriction sites were introduced immediately in front of the start ATG by digestion with HindIII and NarI and religation in the presence of the following annealed oligonucleotides

#### 10 AGCTTGTTAACATGTATCCAACCCTCACCTTCGTGG ACAATTGTACATAGGTTGGGAGTGGAAGCACCGC

No introns were found in the clones sequenced.

The clone 1 type (SEQ.ID.No.3) can be aligned with all ten peptide sequences (see Figure 8) showing 100% identity. Alignment of the two protein sequences encoded by the genes isolated from the fungal infected algae *Gracilariopsis lemaneiformis* shows about 78% identity, indicating that both genes are coding for a  $\alpha$ -1.4-glucan lyase.

20

30

5

# 5. EXPRESSION OF THE GL GENE IN MICRO-ORGANISMS (E.G. ANALYSES OF PICHIA LYASE TRANSFORMANTS AND ASPERGILLUS LYASE TRANSFORMANTS)

The DNA sequence encoding the GL was introduced into microorganisms to produce an enzyme with high specific activity and in large quantities.

In this regard, gene 1 (i.e. SEQ. I.D. No. 3) was cloned as a NotI-HindIII blunt ended (using the DNA blunting kit from Amersham International) fragment into the *Pichia* expression vector pHIL-D2 (containing the AOX1 promoter) digested with EcoRI and blunt ended (using the DNA blunting kit from Amersham International) for expression in *Pichia pastoris* (according to the protocol stated in the *Pichia* 

Expression Kit supplied by Invitrogen).

WO 95/10618

In another embodiment, the gene 1 (i.e. SEQ. I.D. No. 3) was cloned as a NotI-HindIII blunt ended fragment (using the DNA blunting kit from Amersham International) into the Aspergillus expression vector pBARMTE1 (containing the methyl tryptophan resistance promoter from *Neuropera crassa*) digested with SmaI for expression in *Aspergillus niger* (Pall et al (1993) Fungal Genet Newslett. vol 40 pages 59-62). The protoplasts were prepared according to Daboussi et al (Curr Genet (1989) vol 15 pp 453-456) using lysing enzymes Sigma L-2773 and the lyticase Sigma L-8012. The transformation of the protoplasts was followed according to the protocol stated by Buxton et al (Gene (1985) vol 37 pp 207-214) except that for plating the transformed protoplasts the protocol laid out in Punt et al (Methods in Enzymology (1992) vol 216 pp 447 - 457) was followed but with the use of 0.6% osmotic stabilised top agarose.

15

10

5

The results showed that lyase activity was observed in the transformed *Pichia pastoris* and *Aspergillus niger*.

#### **5.1 GENERAL METHODS**

20

25

Preparation of cell-free extracts.

The cells were harvested by centrifugation at 9000 rpm for 5 min and washed with 0.9% NaCl and resuspended in the breaking buffer (50mM K-phosphate, pH 7.5 containing 1mM of EDTA, and 5% glycerol). Cells were broken using glass beads and vortex treatment. The breaking buffer contained 1 mM PMSF (protease inhibitor). The lyase extract (supernatant) was obtained after centrifugation at 9000 rpm for 5 min followed by centrifugation at 20,000 xg for 5min.

Assay of lyase activity by alkaline 3,5-dinitrosalicylic acid reagent (DNS)

One volume of lyase extract was mixed with an equal volume of 4% amylopectin

solution. The reaction mixture was then incubated at a controlled temperature and samples vere removed at specified intervals and analyzed for AF.

The lyase activity was also analyzed using a radioactive method.

5

The reaction mixture contained 10  $\mu$ l <sup>14</sup>C-starch solution (1  $\mu$ Ci; Sigma Chemicals Co.) and 10  $\mu$ l of the lyase extract. The reaction mixture was left at 25°C overnight and was then analyzed in the usual TLC system. The radioactive AF produced was detected using an Instant Imager (Pachard Instrument Co., Inc., Meriden, CT).

10

15

20

Electrophoresis and Western blotting

SDS-PAGE was performed using 8-25% gradient gels and the PhastSystem (Pharmacia). Western blottings was also run on a Semidry transfer unit of the PhastSystem.

Primary antibodies raised against the lyase purified from the red seaweed collected at Qingdao (China) were used in a dilution of 1:100. Pig antirabbit IgG conjugated to alkaline phosphatase (Dako A/S, Glostrup, Denmark) were used as secondary antibodies and used in a dilution of 1:1000.

Part I, Analysis of the Pichia transformantscontaining the above mentioned construct

25 Results:

26

1. Lyase activity was determined 5 days after induction (according to the manual) and proved the activity to be intracellular for all samples in the B series.

Samples of B series: 11 12 13 15 26 27 28 29 30													
Specific activity:		81				253	199	198	150				

\*Specific activity is defined as nmol AF released per min per mg protein in a reaction mixture containing 2% (w/v) of glycogen, 1% (w/v) glycerol in 10 mM potassium phosphate buffer (pH 7.5). The reaction temperature was 45°C; the reaction time was 60 min.

A time course of sample B27 is as follows. The data are also presented in Figure 1.

15	Time (min	) 0	10	20	30	30 40 50				
	Spec. act.	0	18	54	90	147	179	253		

Assay conditions were as above except that the time was varied.

20

5

10

2. Western-blotting analysis.

The CFE of all samples showed bands with a molecular weight corresponding to the native lyase.

25

27 MC-Lyase expressed intracellularly in Pichia pastoris Names of culture Specific activity\* 5 A18 10 A20 . 32 10 A21 8 A22 8 A24 6

Part II, The Aspergilus transformants

#### Results

20

30

15

I. Lyase activity was determined after 5 days incubation(minimal medium containing 0.2% casein enzymatic hydrolysate analysis by the alkaline 3,5-dinitrosalicylic acid reagent

25 1). Lyase activity analysis of the culture medium

Among 35 cultures grown with 0.2% amylopectin included in the culture medium, AF was only detectable in two cultures. The culture medium of 5.4+ and 5.9+ contained 0.13 g AF/liter and 0.44 g/liter, respectively. The result indicated that active lyase had been secreted from the cells. Lyase activity was also measurable in the cell-free extract.

#### 2). Lyase activity analysis in cell-free extracts

	Name of the culture	Specific activity*
5	5.4+	51
	5.9+	148
10	5.13	99
	5.15	25
	5.19	37
15		

20

25

30

\*The specific activity was defined as nmol of AF produced per min per mg protein at 25°C. + indicates that 0.2% amylopectin was added.

The results show that Gene 1 of GL was expressed intracellular in A. niger.

Experiments with transformed E.coli (using cloning vectors pQE30 from the Qia express vector kit from Qiagen) showed expression of enzyme that was recognised by anti-body to the enzyme purified from fungally infected *Gracilariopsis* lemaneiformis.

Instead of Aspergillus niger as host, other industrial important microorganisms for which good expression systems are known could be used such as: Aspergillus oryzae, Aspergillus sp., Trichoderma sp., Saccharomyces cerevisiae, Kluyveromyces sp., Hansenula sp., Pichia sp., Bacillus subtilis, B. amyloliquefaciens, Bacillus sp., Streptomyces sp. or E. coli.

5

10

15

20

Other preferred embodiments of the present invention include any one of the following: A transformed host organism having the capability of producing AF as a consequence of the introduction of a DNA sequence as herein described; such a transformed host organism which is a microorganism - preferably wherein the host organism is selected from the group consisting of bacteria, moulds, fungi and yeast; preferably the host organism is selected from the group consisting of Saccharomyces, Kluyveromyces, Aspergillus, Trichoderma Hansenula, Pichia, Bacillus Streptomyces, Eschericia such as Aspergillus oryzae, Saccharomyces cerevisiae, bacillus sublilis, Bacillus amyloliquefascien, Eschericia coli.; A method for preparing the sugar 1,5-Danhydrofructose comprising contacting an alpha 1,4-glucan (e.g. starch) with the enzyme  $\alpha$ -1,4-glucan lyase expressed by a transformed host organism comprising a nucleotide sequence encoding the same, preferably wherein the nucleotide sequence is a DNA sequence, preferably wherein the DNA sequence is one of the sequences hereinbefore described; A vector incorporating a nucleotide sequence as hereinbefore described, preferably wherein the vector is a replication vector, preferably wherein the vector is an expression vector containing the nucleotide sequence downstream from a promoter sequence, the vector preferably containing a marker (such as a resistance marker); Cellular organisms, or cell line, transformed with such a vector; A method of producing the product  $\alpha$ -1,4-glucan lyase or any nucleotide sequence or part thereof coding for same, which comprises culturing such an organism (or cells from a cell line) transfected with such a vector and recovering the product.

Other modifications of the present invention will be apparent to those skilled in the art without departing from the scope of the invention.

PCT/EP94/03399 WO 95/10618

30

#### SEQUENCE LISTING

#### (1) GENERAL INFORMATION:

- (i) APPLICANT:
  - (A) NAME: DANISCO A/S
  - (B) STREET: LANGEBROGADE 1
  - (C) CITY: COPENHAGEN
  - (D) STATE: COPENHAGEN K
  - (E) COUNTRY: DENMARK
  - (F) POSTAL CODE (ZIP): DK-1001
- (ii) TITLE OF INVENTION: ENZYME
- (iii) NUMBER OF SEQUENCES: 20
- (iv) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
- (v) CURRENT APPLICATION DATA:

APPLICATION NUMBER: WO PCT/EP94/03399

- (2) INFORMATION FOR SEQ ID NO: 1:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 1088 amino acids (B) TYPE: amino acid

    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: protein
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Met Phe Ser Thr Leu Ala Phe Val Ala Pro Ser Ala Leu Gly Ala Ser

Thr Phe Val Gly Ala Glu Val Arg Ser Asn Val Arg Ile His Ser Ala

Phe Pro Ala Val His Thr Ala Thr Arg Lys Thr Asn Arg Leu Asn Val

Ser Met Thr Ala Leu Ser Asp Lys Gln Thr Ala Thr Ala Gly Ser Thr

Asp Asn Pro Asp Gly Ile Asp Tyr Lys Thr Tyr Asp Tyr Val Gly Val 65 70 75 80

Trp Gly Phe Ser Pro Leu Ser Asn Thr Asn Trp Phe Ala Ala Gly Ser

#### **SUBSTITUTE SHEET (RULE 26)**

Ser	Thr	Pro	Gly 100	Gly	Ile	Thr	Asp	Trp 105	Thr	Ala	Thr	Met	Asn 110	Val	Asn
Phe	Asp	Arg 115	Ile	Asp	Asn	Pro	Ser 120	Ile	Thr	Val	Gln	His 125	Pro	Val	Gln
Val	Gln 130	Val	Thr	Ser	Tyr	Asn 135	Asn	Asn	Ser	Tyr	Arg 140	Val	Arg	Phe	Asn
Pro 145	Asp	Gly	Pro	Ile	Arg 150	Asp	Val	Thr	Arg	Gly 155	Pro	Ile	Leu	Lys	Gln 160
Gln	Leu	Asp	Trp	Ile 165	Arg	Thr	Gln	G7 u	Leu 170	Ser	Glu	Gly	Cys	Asp 175	Pro
Gly	Met	Thr	Phe 180	Thr	Ser	Glu	Gly	Phe 185	Leu	Thr	Phe	Glu	Thr 190	Lys	Asp
Leu	Ser	Val 195	Ile	Ile	Tyr	Gly	Asn 200	Phe	Lys	Thr	Arg	Va1 205	Thr	Arg	Lys
Ser	Asp 210	G1 <i>y</i>	Lys	Val	Ile	Met 215	Glu	Asn	Asp	G1u	Va1 220	Gly	Thr	Ala	Ser
Ser 225	Gly	Asn	Lys	Cys	Arg 230	G1y	Leu	Met	Phe	Val 235	Asp	Arg	Leu	Tyr	G1y 240
Asn	Ala	Ile	Ala	Ser 245	Val	Asn	Lys	Asn	Phe 250	Arg	Asn	Asp	Ala	Va1 255	Lys
Gln	G1u	Gly	Phe 260	Tyr	Gly	Ala	Gly	G1 u 265	Val	Asn	Cys	Lys	Tyr 270	Gln	Asp
Thr	Tyr	Ile 275	Leu	G1u	Arg	Thr	G1y 280	Ile	Ala	Met	Thr	Asn 285	Tyr	Asn	Tyr
Asp	Asn 290	Leu	Asn	Tyr	Asn	G1n 295	Trp	Asp	Leu	Arg	Pro <b>30</b> 0	Pro	His	His	Asp
G1 <i>y</i> 305	Ala	Leu	Asn	Pro	Asp 310	Tyr	Tyr	Ile	Pro	Met 315	Tyr	Tyr	A1 a	Ala	Pro 320
Trp	Leu	Ile	Val	Asn 325	Gly	Cys	Ala	Gly	Thr 330	Ser	G1u	Gln	Tyr	Ser 335	Tyr
Gly	Trp	Phe	Met 340	Asp	Asn	Val	Ser	G1 n 345	Ser	Tyr	Met	Asn	Thr 350	Gly	Asp
Thr	Thr	Trp 355	Asn	Ser	Gly	Gln	G1u 360	Asp	Leu	Ala	Tyr	Met 365	Gly	Ala	Gln
Tyr	Gly 370	Pro	Phe	Asp	Gln	His 375	Phe	Val	Tyr	Gly	Ala 380	Gly	Gly	Gly	Met
G1u 385	Cys	Va1	Va1	Thr	A1a 390	Phe	Ser	Leu	Leu	G1n 395	Gly	Lys	Glu	Phe	G1u 400

								32							
Asn	Gln	Val	Leu	Asn 405	Lys	Arg	Ser	Val	Met 410	Pro	Pro	Lys	Tyr	Val 415	Phe
Gly	Phe	Phe	G1n 420	Gly	Val	Phe	Gly	Thr 425	Ser	Ser	Leu	Leu	Arg 430	Ala	His
Met	Pro	Ala 435	Gly	Glu	Asn	Asn	Ile 440	Ser	Val	Glu	Glu	Ile 445	Val	Glu	Gly
Tyr	G1n 450	Asn	Asn	Asn	Phe	Pro 455	Phe	Glu	Gly	Leu	A1 a 460	Val	Asp	Val	Asp
Met 465	Gln	Asp	Asn	Leu	Arg 470	Val	Phe	Thr	Thr	Lys 475	Gly	G1u	Phe	Trp	Thr 480
Ala	Asn	Arg	Val	G1y 485	Thr	Gly	G1y	Asp	Pro 490	Asn	Asn	Arg	Ser	Val 495	Phe
Glu	Trp	Ala	His 500	Asp	Lys	Gly	Leu	Va1 505	Cys	Gln	Thr	Asn	Ile 510	Thr	Cys
Phe	Leu	Arg 515	Asn	Asp	Asn	Glú	G1y 520	Gln	Asp	Tyr	G1 u	Val 525	Asn	Gln	Thr
Leu	Arg 530	Glu	Arg	Gln	Leu	Tyr 535	Thr	Lys	Asn	Asp	Ser 540	Leu	Thr	Gly	Thr
Asp 545	Phe	Gly	Met	Thr	Asp 550	Asp	Gly	Pro	Ser	Asp 555	Ala	Tyr	Ile	Gly	His 560
Leu	Asp	Tyr	G1y	Gly 565	Gly	Val	G1u	Cys	Asp 570	Ala	Leu	Phe	Pro	Asp 575	Trp
Gly	Arg.	Pro	Asp 580	Val	Ala	G1u	Trp	Trp 585	Gly	Asn	Asn	Tyr	Lys 590	Lys	Leu
Phe	Ser	Ile 595	Gly-	Leu	Asp	Phe	Val 600	Trp	Gln	Asp	Met	Thr 605	Val	Pro	A1 a
Met	Met 610	Pro	His	Lys	Ile	Gly 615	Asp	Asp	Ile	Asn	Va1 620	Lys	Pro	Asp	Gly
Asn 625	Trp	Pro	Asn	Ala	Asp 630	Asp	Pro	Ser	Asn	Gly 635	Gln	Tyr	Asn	Trp	Lys 640
Thr	Tyr	His	Pro	G1n 645	Val	Leu	Val	Thr	Asp 650	Met	Arg	Tyr	Glu	Asn 655	His
Gly	Arg	Glu	Pro 660	Met	Val	Thr	G1n	Arg 665	Asn	Ile	His	Ala	Tyr 670	Thr	Leu
Cys	G1u	Ser 675	Thr	Arg	Lys	Glu	Gly 680	Ile	Val	Glu	Asn	Ala 685	Asp	Thr	Leu
Thr	Lys 690	Phe	Arg	Arg	Ser	Tyr 695	Ile	Ile	Ser	Arg	Gly 700	Gly	Tyr	Ile	Gly

Asn 705	G1n	His	Phe	Gly	Gly 710	Met	Trp	Va1	Gly	Asp 715	Asn	Ser	Thr	Thr	Ser 720
Asn	Tyr	Ile	G1n	Met 725	Met	Ile	Ála	Asn	Asn 730	Ile	Asn	Met	Asn	Met 735	Ser
Cys	Leu	Pro	Leu 740	Val	Gly	Ser	Asp	Ile 745	Gly	G1y	Phe	Thr	Ser 750	Tyr	Asp
Asn	G1u	Asn 755	G1n	Arg	Thr	Pro	Cys 760	Thr	Gly	Asp	Leu	Met 765	Val	Arg	Tyr
Val	G1n 770	Ala	G1y	Cys	Leu	Leu 775	Pro	Trp	Phe	Arg	Asn 780	His	Tyr	Asp	Arg
Trp <b>785</b>	Ile	Glu	Ser	Lys	Asp 790	His	Gly	Lys	Asp	Tyr <b>79</b> 5	Gln	Glu	Leu	Tyr	Met 800
Tyr	Pro	Asn	Glu	Met 805	Asp	Thr	Leu	Arg	Lys 810	Phe	Val	Glu	Phe	Arg 815	Tyr
Arg	Trp	Gln	G1 u 820	Val	Leu	Tyr	Thr	A1a 825	Met	Tyr	G1n	Asn	A1a 830	Ala	Phe
Gly	Lys	Pro 835	Пe	Ile	Lys	Ala	A1 a 840	Ser	Met	Tyr	Asn	Asn 845	Asp	Ser	Asn
Va1	Arg 850	Arg	A1 a	Gln	Asn	Asp 855	His	Phe	Leu	Leu	Gly 860	Gly	His	Asp	Gly
Tyr 865	Arg	Ile	Leu	Cys	Ala 870	Pro	Val	Va.1	Trp	G1u 875	Asn	Ser	Thr	Glu	Arg 880
G1u	Leu	Tyr	Leu	Pro 885	Val	Leu	Thr	Gln	Trp 8 <b>9</b> 0	Tyr	Lys	Phe	Gly	Pro 895	Asp
Phe	Asp	Thr	Lys 900	Pro	Leu	Glu	G1 y	A1a 905	Met	Asn	Gly	Gly	Asp <b>9</b> 10	Arg	Ile
Tyr	Asn	Tyr 915	Pro	Val	Pro	Gln	Ser 920	Glu	Ser	Pro	Ile	Phe 925	Val	Arg	Glu
Gly	A1 a 930	Ile	Leu	Pro	Thr	Arg 935	Tyr	Thr	Leu	Asn	Gly 940	Glu	Asn	Lys	Ser
Leu 945	Asn	Thr	Tyr	Thr	Asp 950	Glu	Asp	Pro	Leu	Va1 955	Phe	Glu	Val	Phe	Pro 960
Leu	Gly	Asn	Asn	Arg 965	Ala	Asp	Gly	Met	Cys 970	Tyr	Leu	Asp	Asp	Gly 975	<b>Gl</b> y
Val	Thr	Thr	Asn 980	Ala	Glu	Asp	Asn	Gly 985	Lys	Phe	Ser	Val	Val 990	Lys	Val
Ala	Ala	G1u 995	Gln	Asp	Gly	Gly	Thr 100		Thr	Ile	Thr	Phe 100		Asn	Asp

PCT/EP94/03399 WO 95/10618

34

Cys Tyr Glu Tyr Val Phe Gly Gly Pro Phe Tyr Val Arg Val Arg Gly 1015

Ala Gln Ser Pro Ser Asn Ile His Val Ser Ser Gly Ala Gly Ser Gln 1025 1030 1035 1040

Asp Met Lys Val Ser Ser Ala Thr Ser Arg Ala Ala Leu Phe Asn Asp 1050

Gly Glu Asn Gly Asp Phe Trp Val Asp Gln Glu Thr Asp Ser Leu Trp 1065

Leu Lys Leu Pro Asn Val Val Leu Pro Asp Ala Val Ile Thr Ile Thr 1080 1085 1075

#### (2) INFORMATION FOR SEQ ID NO: 2:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 1091 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

#### (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Tyr Pro Thr Leu Thr Phe Val Ala Pro Ser Ala Leu Gly Ala Arg

Thr Phe Thr Cys Val Gly Ile Phe Arg Ser His Ile Leu Ile His Ser 25

Val Val Pro Ala Val Arg Leu Ala Val Arg Lys Ser Asn Arg Leu Asn

Val Ser Met Ser Ala Leu Phe Asp Lys Pro Thr Ala Val Thr Gly Gly

Lys Asp Asn Pro Asp Asn Ile Asn Tyr Thr Thr Tyr Asp Tyr Val Pro

Val Trp Arg Phe Asp Pro Leu Ser Asn Thr Asn Trp Phe Ala Ala Gly

Ser Ser Thr Pro Gly Asp Ile Asp Asp Trp Thr Ala Thr Met Asn Val 100

Asn Phe Asp Arg Ile Asp Asn Pro Ser Phe Thr Leu Glu Lys Pro Val

Gln Val Gln Val Thr Ser Tyr Lys Asn Asn Cys Phe Arg Val Arg Phe 135 140

Asn Pro Asp Gly Pro Ile Arg Asp Val Asp Arg Gly Pro Ile Leu Gln Gln Gln Leu Asn Trp Ile Arg Lys Gln Glu Gln Ser Lys Gly Phe Asp Pro Lys Met Gly Phe Thr Lys Glu Gly Phe Leu Lys Phe Glu Thr Lys 185 Asp Leu Asn Val Ile Ile Tyr Gly Asn Phe Lys Thr Arg Val Thr Arg Lys Arg Asp Gly Lys Gly Ile Met Glu Asn Asn Glu Val Pro Ala Gly Ser Leu Gly Asn Lys Cys Arg Gly Leu Met Phe Val Asp Arg Leu Tyr 235 Gly Thr Ala Ile Ala Ser Val Asn Glu Asn Tyr Arg Asn Asp Pro Asp Arg Lys Glu Gly Phe Tyr Gly Ala Gly Glu Val Asn Cys Glu Phe Trp Asp Ser Glu Gln Asn Arg Asn Lys Tyr Ile Leu Glu Arg Thr Gly Ile Ala Met Thr Asn Tyr Asn Tyr Asp Asn Tyr Asn Tyr Asn Gln Ser Asp Leu Ile Ala Pro Gly Tyr Pro Ser Asp Pro Asn Phe Tyr Ile Pro Met 315 Tyr Phe Ala Ala Pro Trp Val Val Val Lys Gly Cys Ser Gly Asn Ser Asp Glu Gln Tyr Ser Tyr Gly Trp Phe Met Asp Asn Val Ser Gln Thr 345 Tyr Met Asn Thr Gly Gly Thr Ser Trp Asn Cys Gly Glu Glu Asn Leu Ala Tyr Met Gly Ala Gln Cys Gly Pro Phe Asp Gln His Phe Val Tyr Gly Asp Gly Asp Gly Leu Glu Asp Val Val Gln Ala Phe Ser Leu Leu Gln Gly Lys Glu Phe Glu Asn Gln Val Leu Asn Lys Arg Ala Val Met Pro Pro Lys Tyr Val Phe Gly Tyr Phe Gln Gly Val Phe Gly Ile Ala 425 Ser Leu Leu Arg Glu Gln Arg Pro Glu Gly Gly Asn Asn Ile Ser Val

								30							
Gln	G1u 450	Ile	Val	Glu	G1y	Tyr 455	G1n	Ser	Asn	Asn	Phe 460	Pro	Leu	Glu	Gly
Leu 465	Ala	Val	Asp	Val	Asp 470	Met	Gln	Gln	Asp	Leu 475	Arg	Val	Phe	Thr	Thr 480
Lys	Ile	G1u	Phe	Trp 485	Thr	Ala	Asn	Lys	Val 490	Gly	Thr	Gly	Gly	Asp 495	Ser
Asn	Asn	Lys	Ser 500	Val	Phe	Glu	Trp	A1 a 505	His	Asp	Lys	Gly	Leu 510	Val	Cys
Gln	Thr	Asn 515	Val	Thr	Cys	Phe	Leu 520	Arg	Asn	Asp	Asn	Gly 525	Gly	Ala	Asp
Tyr	G1u 530	Val	Asn	G1n	Thr	Leu 535	Arg	Glu	Lys	Gly	Leu 540	Tyr	Thr	Lys	Asn
Asp 545	Ser	Leu	Thr	Asn	Thr 550	Asn	Phe	Gly	Thr	Thr 555	Asn	Asp	Gly	Pro	Ser 560
Asp	Ala	Tyr	Ile	G1 y 565	His	Leu Leu	Asp	Tyr	Gly <b>57</b> 0	Gly	Gly	Gly	Asn	Cys 575	Asp
Ala	Leu	Phe	Pro 580	Asp	Trp	Gly	Arg	Pro 585	Gly	Val	Ala	Glu	Trp 590	Trp	Gly
Asp	Asn	Tyr 595	Ser	Lys	Leu	Phe	Lys 600	Ile	Gly	Leu	Asp	Phe 605	Val	Trp	Gln
Asp	Met 610	Thr	Val	Pro	Ala	Met 615	Met	Pro	His	Lys	Va1 620	Gly	Asp	Ala	Val
Asp 625	Thr	Arg	Ser	Pro	Tyr 630	Gly	Trp	Pro	Asn	G1 u 635	Asn	Asp	Pro	Ser	Asn 640
Gly	Arg	Tyr	Asn	Trp 645	Lys	Ser	Tyr	His	Pro 650	Gln	Val	Leu	Val	Thr 655	Asp
Met	Arg	Tyr	G1 u 660	Asn	His	Gly	Arg	G1 u 665	Pro	Met	Phe	Thr	G1n 670	Arg	Asn
Met	His	Ala 675	Tyr	Thr	Leu	Cys	G1u 680	Ser	Thr	Arg	Lys	G1u 685	Gly	Ile	Va1
Ala	Asn 690	Ala	Asp	Thr	Leu	Thr 695	Lys	Phe	Arg	Arg	Ser 700	Tyr	Ile	Ile	Ser
Arg 705	Gly	Gly	Tyr	Ile	Gly 710	Asn	Gln	His	Phe	Gly 715	Gly	Met	Trp	Val	Gly 720
Asp	Asn	Ser	Ser	Ser 725	Gln	Arg	Tyr	Leu	G1n 730	Met	Met	Ile	Ala	Asn 735	Ile
Val	Asn	Met	Asn 740	Met	Ser	Cys	Leu	Pro 745	Leu	Val	Gly	Ser	Asp <b>75</b> 0	Ile	Gly

Gly	Phe	Thr 755	Ser	Tyr	Asp	Gly	Arg 760	Asn	Val	Cys	Pro	Gly 765	Asp	Leu	Met
Val	Arg 770	Phe	Val	Gln	Ala	G1y 775	Cys	Leu	Leu	Pro	Trp 780	Phe	Arg	Asn	His
Tyr 785	Gly	Arg	Leu	Val	G1u 790	Gly	Lys	Gln	Glu	Gly 795	Lys	Tyr	Tyr	Gln	G1u 800
Leu	Tyr	Met	Tyr	Lys 805	Asp	Glu	Met	Ala	Thr 810	Leu	Arg	Lys	Phe	11e 815	Glu
Phe	Arg	Tyr	Arg 820	Trp	Gln	Glu	Val	Leu 825	Tyr	Thr	Ala	Met	Tyr 830	Gln	Asn
Ala	Ala	Phe 835	Gly	Lys	Pro	Ile	Ile 840	Lys	Ala	Ala	Ser	Met 845	Tyr	Asp	Asn
Asp	Arg 850	Asn	Val	Arg	Gly	A1 a 855	Gln	Asp	Asp	His	Phe 860	Leu	Leu	Gly	G1y
His <b>865</b>	Asp	Gly	Tyr	Arg	Ile 870	Leu	Cys	Ala	Pro	Va1 875	Val	Trp	Glu	Asn	Thr 880
Thr	Ser	Arg	Asp	Leu 885	Tyr	Leu	Pro	Val	Leu 890	Thr	Lys	Trp	Tyr	Lys 895	Phe
Gly	Pro	Asp	Tyr 900	Asp	Thr	Lys	Arg	Leu 905	Asp	Ser	Ala	Leu	Asp 910	Gly	Gly
G1n	Met	Ile 915	Lys	Asn	Tyr	Ser	Val 920	Pro	Gln	Ser	Asp	Ser 925	Pro	Ile	Phe
Va1	Arg <b>9</b> 30	Glu	Gly	Ala	Ile	Leu 935	Pro	Thr	Arg	Tyr	Thr 940	Leu	Asp	Gly	Ser
Asn 945	Lys	Ser	Met	Asn	Thr 950	Tyr	Thr	Asp	Lys	Asp 955	Pro	Leu	Val	Phe	G1u 960
Val	Phe	Pro	Leu	G1y 965	Asn	Asn	Arg	Ala	Asp 970	<b>61</b> y	Met	Cys	Tyr	Leu 975	Asp
Asp	G1y	G1y	Ile 980	Thr	Thr	Asp	Ala	G1 u 985	Asp	His	Gly	Lys	Phe 990	Ser	Val
Ile	Asn	Va1 995	Glu	Ala	Leu	Arg	Lys 1000		Val	Thr	Thr	Thr 100		Lys	Phe
Ala	Tyr 1010		Thr	Tyr	Gln	Tyr 101		Phe	Asp	Gly	Pro 1020		Tyr	Va1	Arg
Ile 1025		Asn	Leu	Thr	Thr 1030		Ser	Lys	Ile	Asn 1035		Ser	Ser	Gly	Ala 1040
Gly	Glu	Glu	Asp	Met		Pro	Thr	Ser	Ala		Ser	Arg	Ala	Ala	Leu

Phe Ser Asp Gly Gly Val Gly Glu Tyr Trp Ala Asp Asn Asp Thr Ser 1060 1065 1070

Ser Leu Trp Met Lys Leu Pro Asn Leu Val Leu Gln Asp Ala Val Ile 1075 1080 1085

Thr Ile Thr 1090

#### (2) INFORMATION FOR SEQ ID NO: 3:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 3267 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

#### (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

ATGTTTTCAA CCCTTGCGTT TGTCGCACCT AGTGCGCTGG GAGCCAGTAC CTTCGTAGGG 60 GCGGAGGTCA GGTCAAATGT TCGTATCCAT TCCGCTTTTC CAGCTGTGCA CACAGCTACT 120 CGCAAAACCA ATCGCCTCAA TGTATCCATG ACCGCATTGT CCGACAAACA AACGGCTACT 180 GCGGGTAGTA CAGACAATCC GGACGGTATC GACTACAAGA CCTACGATTA CGTCGGAGTA 240 TGGGGTTTCA GCCCCCTCTC CAACACGAAC TGGTTTGCTG CCGGCTCTTC TACCCCGGGT 300 GGCATCACTG ATTGGACGGC TACAATGAAT GTCAACTTCG ACCGTATCGA CAATCCGTCC 360 ATCACTGTCC AGCATCCCGT TCAGGTTCAG GTCACGTCAT ACAACAACAA CAGCTACAGG 420 GTTCGCTTCA ACCCTGATGG CCCTATTCGT GATGTGACTC GTGGGCCTAT CCTCAAGCAG 480 CAACTAGATT GGATTCGAAC GCAGGAGCTG TCAGAGGGAT GTGATCCCGG AATGACTTTC 540 ACATCAGAAG GTTTCTTGAC TTTTGAGACC AAGGATCTAA GCGTCATCAT CTACGGAAAT 600 TTCAAGACCA GAGTTACGAG AAAGTCTGAC GGCAAGGTCA TCATGGAAAA TGATGAAGTT 660 GGAACTGCAT CGTCCGGGAA CAAGTGCCGG GGATTGATGT TCGTTGATAG ATTATACGGT 720 AACGCTATCG CTTCCGTCAA CAAGAACTTC CGCAACGACG CGGTCAAGCA GGAGGGATTC 780 TATGGTGCAG GTGAAGTCAA CTGTAAGTAC CAGGACACCT ACATCTTAGA ACGCACTGGA 840 ATCGCCATGA CAAATTACAA CTACGATAAC TTGAACTATA ACCAGTGGGA CCTTAGACCT 900 CCGCATCATG ATGGTGCCCT CAACCCAGAC TATTATATTC CAATGTACTA CGCAGCACCT 960 TGGTTGATCG TTAATGGATG CGCCGGTACT TCGGAGCAGT ACTCGTATGG ATGGTTCATG 1020

GACAATGTCT CTCAATCTTA CATGAATACT GGAGATACTA CCTGGAATTC TGGACAAGAG	1080
GACCTGGCAT ACATGGGCGC GCAGTATGGA CCATTTGACC AACATTTTGT TTACGGTGCT	1140
GGGGGTGGGA TGGAATGTGT GGTCACAGCG TTCTCTCTTC TACAAGGCAA GGAGTTCGAG	1200
AACCAAGTTC TCAACAAACG TTCAGTAATG CCTCCGAAAT ACGTCTTTGG TTTCTTCCAG	1260
GGTGTTTTCG GGACTTCTTC CTTGTTGAGA GCGCATATGC CAGCAGGTGA GAACAACATC	1320
TCAGTCGAAG AAATTGTAGA AGGTTATCAA AACAACAATT TCCCTTTCGA GGGGCTCGCT	1380
GTGGACGTGG ATATGCAAGA CAACTTGCGG GTGTTCACCA CGAAGGGCGA ATTTTGGACC	1440
GCAAACAGGG TGGGTACTGG CGGGGATCCA AACAACCGAT CGGTTTTTGA ATGGGCACAT	1500
GACAAAGGCC TTGTTTGTCA GACAAATATA ACTTGCTTCC TGAGGAATGA TAACGAGGGG	1560
CAAGACTACG AGGTCAATCA GACGTTAAGG GAGAGGCAGT TGTACACGAA GAACGACTCC	1620
CTGACGGGTA CGGATTTTGG AATGACCGAC GACGGCCCCA GCGATGCGTA CATCGGTCAT	1680
CTGGACTATG GGGGTGGAGT AGAATGTGAT GCACTTTTCC CAGACTGGGG ACGGCCTGAC	1740
GTGGCCGAAT GGTGGGGAAA TAACTATAAG AAACTGTTCA GCATTGGTCT CGACTTCGTC	1800
TGGCAAGACA TGACTGTTCC AGCAATGATG CCGCACAAAA TTGGCGATGA CATCAATGTG	1860
AAACCGGATG GGAATTGGCC GAATGCGGAC GATCCGTCCA ATGGACAATA CAACTGGAAG	1920
ACGTACCATC CCCAAGTGCT TGTAACTGAT ATGCGTTATG AGAATCATGG TCGGGAACCG	1980
ATGGTCACTC AACGCAACAT TCATGCGTAT ACACTGTGCG AGTCTACTAG GAAGGAAGGG	2040
ATCGTGGAAA ACGCAGACAC TCTAACGAAG TTCCGCCGTA GCTACATTAT CAGTCGTGGT	2100
GGTTACATTG GTAACCAGCA TTTCGGGGGT ATGTGGGTGG GAGACAACTC TACTACATCA	2160
AACTACATCC AAATGATGAT TGCCAACAAT ATTAACATGA ATATGTCTTG CTTGCCTCTC	2220
GTCGGCTCCG ACATTGGAGG ATTCACCTCA TACGACAATG AGAATCAGCG AACGCCGTGT	2280
ACCGGGGACT TGATGGTGAG GTATGTGCAG GCGGGCTGCC TGTTGCCGTG GTTCAGGAAC	2340
CACTATGATA GGTGGATCGA GTCCAAGGAC CACGGAAAGG ACTACCAGGA GCTGTACATG	2400
TATCCGAATG AAATGGATAC GTTGAGGAAG TTCGTTGAAT TCCGTTATCG CTGGCAGGAA	2460
GTGTTGTACA CGGCCATGTA CCAGAATGCG GCTTTCGGAA AGCCGATTAT CAAGGCTGCT	2520
TCGATGTACA ATAACGACTC AAACGTTCGC AGGGCGCAGA ACGATCATTT CCTTCTTGGT	2580
GGACATGATG GATATCGCAT TCTGTGCGCG CCTGTTGTGT GGGAGAATTC GACCGAACGC	2640
GAATTGTACT TGCCCGTGCT GACCCAATGG TACAAATTCG GTCCCGACTT TGACACCAAG	2700

PCT/EP94/03399

#### 37/3

CCT	CTGGAAG	GAGCGATGAA	CGGAGGGGAC	CGAATTTACA	ACTACCCTGT	ACCGCAAAGT	2760
GAA <sup>-</sup>	TCACCAA	TCTTCGTGAG	AGAAGGTGCG	ATTCTCCCTA	CCCGCTACAC	GTTGAACGGT	2820
GAA/	AACAAAT	CATTGAACAC	GTACACGGAC	GAAGATCCGT	TGGTGTTTGA	AGTATTCCCC	2880
CTC	GGAAACA	ACCGTGCCGA	CGGTATGTGT	TATCTTGATG	ATGGCGGTGT	GACCACCAAT	2940
GCT	GAAGACA	ATGGCAAGTT	CTCTGTCGTC	AAGGTGGCAG	CGGAGCAGGA	TGGTGGTACG	3000
GAG/	ACGATAA	CGTTTACGAA	TGATTGCTAT	GAGTACGTTT	TCGGTGGACC	GTTCTACGTT	3060
CGA	GTGCGCG	GCGCTCAGTC	GCCGTCGAAC	ATCCACGTGT	CTTCTGGAGC	GGGTTCTCAG	3120
GAC/	ATGAAGG	TGAGCTCTGC	CACTTCCAGG	GCTGCGCTGT	TCAATGACGG	GGAGAACGGT	3180
GAT	TTCTGGG	TTGACCAGGA	GACAGATTCT	CTGTGGCTGA	AGTTGCCCAA	CGTTGTTCTC	3240
CCG	GACGCTG	TGATCACAAT	TACCTAA				3267

### (2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 3276 base pairs
  - (B) TYPE: nucleic acid (C) STRANDEDNESS: double

  - (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

60	TTTCACGTGT	GGGCCAGAAC	AGTGCGCTAG	CGTGGCGCCT	CCCTCACCTT	ATGTATCCAA
120	GCGTCTAGCT	TTCCAGCGGT	CATTCGGTTG	CATTCTTATT	TTAGGTCACA	GTGGGCATTT
180	ACCGACTGCT	TGTTCGACAA	ATGTCCGCTT	CAATGTATCC	GCAACCGCCT	GTGCGCAAAA
240	CTACGTCCCT	CCACTTATGA	ATCAATTACA	CCCGGACAAT	GGAAGGACAA	GTTACTGGAG
300	TTCCACTCCC	CTGCCGGATC	AACTGGTTTG	CAGCAATACG	TCGACCCCCT	GTGTGGCGCT
360	CGACAATCCA	TCGACCGTAT	AATGTGAACT	GGCGACAATG	ACGACTGGAC	GGCGATATTG
420	CAATTGTTTC	CATACAAGAA	CAGGTCACGT	GGTTCAGGTT	TCGAGAAACC	TCCTTCACTC
480	TATCCTCCAG	ATCGTGGGCC	CGCGATGTGG	TGGTCCTATT	TCAACCCTGA	AGGGTTCGCT
540	TAAGATGGGC	GGTTTGATCC	CAGTCGAAGG	GAAGCAGGAG	ATTGGATCCG	CAGCAACTAA
600	CATATATGGC	TGAACGTTAT	ACCAAGGATC	GAAATTTGAG	AAGGTTTCTT	TTCACAAAAG
660	GAATAATGAA	GGATCATGGA	GATGGAAAAG	GAGGAAGAGG	CTAGAGTTAC	AATTTTAAGA

GTGCCGGCAG	GATCGTTAGG	GAACAAGTGC	CGGGGATTGA	TGTTTGTCGA	CAGGTTGTAC	720
GGCACTGCCA	TCGCTTCCGT	TAATGAAAAT	TACCGCAACG	ATCCCGACAG	GAAAGAGGGG	780
TTCTATGGTG	CAGGAGAAGT	AAACTGCGAG	TTTTGGGACT	CCGAACAAA	CAGGAACAAG	840
TACATCTTAG	AACGAACTGG	AATCGCCATG	ACAAATTACA	ATTATGACAA	CTATAACTAC	900
AACCAGTCAG	ATCTTATTGC	TCCAGGATAT	CCTTCCGACC	CGAACTTCTA	CATTCCCATG	960
TATTTTGCAG	CACCTTGGGT	AGTTGTTAAG	GGATGCAGTG	GCAACAGCGA	TGAACAGTAC	1020
TCGTACGGAT	GGTTTATGGA	TAATGTCTCC	CAAACTTACA	TGAATACTGG	TGGTACTTCC	1080
TGGAACTGTG	GAGAGGAGAA	CTTGGCATAC	ATGGGAGCAC	AGTGCGGTCC	ATTTGACCAA	1140
CATTTTGTGT	ATGGTGATGG	AGATGGTCTT	GAGGATGTTG	TCCAAGCGTT	стстсттстс	1200
CAAGGCAAAG	AGTTTGAGAA	CCAAGTTCTG	AACAAACGTG	CCGTAATGCC	TCCGAAATAT	1260
GTGTTTGGTT	ACTTTCAGGG	AGTCTTTGGG	ATTGCTTCCT	TGTTGAGAGA	GCAAAGACCA	1320
GAGGGTGGTA	ATAACATCTC	TGTTCAAGAG	ATTGTCGAAG	GTTACCAAAG	CAATAACTTC	1380
CCTTTAGAGG	GGTTAGCCGT	AGATGTGGAT	ATGCAACAAG	ATTTGCGCGT	GTTCACCACG	1440
AAGATTGAAT	TTTGGACGGC	AAATAAGGTA	GGCACCGGGG	GAGACTCGAA	TAACAAGTCG	1500
GTGTTTGAAT	GGGCACATGA	CAAAGGCCTT	GTATGTCAGA	CGAATGTTAC	TTGCTTCTTG	1560
AGAAACGACA	ACGGCGGGGC	AGATTACGAA	GTCAATCAGA	CATTGAGGGA	GAAGGGTTTG	1620
TACACGAAGA	ATGACTCACT	GACGAACACT	AACTTCGGAA	CTACCAACGA	CGGGCCGAGC	1 <b>6</b> 80
GATGCGTACA	TTGGACATCT	GGACTATGGT	GGCGGAGGGA	ATTGTGATGC	ACTTTTCCCA	1740
GACTGGGGTC	GACCGGGTGT	GGCTGAATGG	TGGGGTGATA	ACTACAGCAA	GCTCTTCAAA	1800
ATTGGTCTGG	ATTTCGTCTG	GCAAGACATG	ACAGTTCCAG	CTATGATGCC	ACACAAAGTT	1860
GGCGACGCAG	TCGATACGAG	ATCACCTTAC	GGCTGGCCGA	ATGAGAATGA	TCCTTCGAAC	1920
GGACGATACA	ATTGGAAATC	TTACCATCCA	CAAGTTCTCG	TAACTGATAT	GCGATATGAG	1980
AATCATGGAA	GGGAACCGAT	GTTCACTCAA	CGCAATATGC	ATGCGTACAC	ACTCTGTGAA	2040
TCTACGAGGA	AGGAAGGGAT	TGTTGCAAAT	GCAGACACTC	TAACGAAGTT	CCGCCGCAGT	2100
TATATTATCA	GTCGTGGAGG	TTACATTGGC	AACCAGCATT	TTGGAGGAAT	GTGGGTTGGA	2160
GACAACTCTT	CCTCCCAAAG	ATACCTCCAA	ATGATGATCG	CGAACATCGT	CAACATGAAC	2220
ATGTCTTGCC	TTCCACTAGT	TGGGTCCGAC	ATTGGAGGTT	TTACTTCGTA	TGATGGACGA	2280
AACGTGTGTC	CCGGGGATCT	AATGGTAAGA	TTCGTGCAGG	CGGGTTGCTT	ACTACCGTGG	2340

TTCAGAAACC	ACTATGGTAG	GTTGGTCGAG	GGCAAGCAAG	AGGGAAAATA	CTATCAAGAA	2400
CTGTACATGT	ACAAGGACGA	GATGGCTACA	TTGAGAAAAT	TCATTGAATT	CCGTTACCGC	2460
TGGCAGGAGG	TGTTGTACAC	TGCTATGTAC	CAGAATGCGG	CTTTCGGGAA	ACCGATTATC	2520
AAGGCAGCTT	CCATGTACGA	CAACGACAGA	AACGTTCGCG	GCGCACAGGA	TGACCACTTC	2580
CTTCTCGGCG	GACACGATGG	ATATCGTATT	TTGTGTGCAC	CTGTTGTGTG	GGAGAATACA	2640
ACCAGTCGCG	ATCTGTACTT	GCCTGTGCTG	ACCAAATGGT	ACAAATTCGG	CCCTGACTAT	2700
GACACCÁAGC	GCCTGGATTC	TGCGTTGGAT	GGAGGGCAGA	TGATTAAGAA	CTATTCTGTG	2760
CCACAAAGCG	ACTCTCCGAT	ATTTGTGAGG	GAAGGAGCTA	TTCTCCCTAC	CCGCTACACG	2820
TTGGACGGTT	CGAACAAGTC	AATGAACACG	TACACAGACA	AAGACCCGTT	GGTGTTTGAG	2880
GTATTCCCTC	TTGGAAACAA	CCGTGCCGAC	GGTATGTGTT	ATCTTGATGA	TGGCGGTATT	2940
ACTACAGATG	CTGAGGACCA	TGGCAAATTC	TCTGTTATCA	ATGTCGAAGC	CTTACGGAAA	3000
GGTGTTACGA	CGACGATCAA	GTTTGCGTAT	GACACTTATC	AATACGTATT	TGATGGTCCA	3060
TTCTACGTTC	GAATCCGTAA	TCTTACGACT	GCATCAAAAA	TTAACGTGTC	TTCTGGAGCG	3120
GGTGAAGAGG	ACATGACACC	GACCTCTGCG	AACTCGAGGG	CAGCTTTGTT	CAGTGATGGA	3180
GGTGTTGGAG	AATACTGGGC	TGACAATGAT	ACGTCTTCTC	TGTGGATGAA	GTTGCCAAAC	3240
ставттстас	AAGACGCTGT	GATTACCATT	ACGTAG			3276

#### (2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 90 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

#### (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Tyr Arg Trp Gln Glu Val Leu Tyr Thr Ala Met Tyr Gln Asn Ala Ala 1 5 10 15

Phe Gly Lys Pro Ile Ile Lys Ala Ala Ser Met Tyr Asn Asn Asp Ser

Asn Val Arg Arg Ala Gln Asn Asp His Phe Leu Leu Gly Gly His Asp 35 40 45

Gly Tyr Arg Ile Leu Cys Ala Pro Val Val Trp Glu Asn Ser Thr Glu

Arg Glu Leu Tyr Leu Pro Val Leu Thr Gln Trp Tyr Lys Phe Gly Pro

Asp Phe Asp Thr Lys Pro Leu Glu Gly Ala

- (2) INFORMATION FOR SEQ ID NO: 6:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 23 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: DNA (genomic)
  - (ix) FEATURE:
    - (A) NAME/KEY: misc\_difference
      (B) LOCATION: replace(6, "")

    - (D) OTHER INFORMATION: /note= "N is T or C"
  - (ix) FEATURE:
    - (A) NAME/KEY: misc difference
    - (B) LOCATION: replace(9, "")
    - (D) OTHER INFORMATION: /note= "N is C or T"
  - (ix) FEATURE:
    - (A) NAME/KEY: misc\_difference
      (B) LOCATION: replace(12, "")

    - (D) OTHER INFORMATION: /note= "N is C or T"
  - (ix) FEATURE:
    - (A) NAME/KEY: misc\_difference
    - (B) LOCATION: replace(15, "")
    - (D) OTHER INFORMATION: /note= "N is C or T"
  - (ix) FEATURE:
    - (A) NAME/KEY: misc difference
    - (B) LOCATION: replace(18, "")
    - (D) OTHER INFORMATION: /note= "N is G or A or T or C"
  - (ix) FEATURE:
    - (A) NAME/KEY: misc difference
    - (B) LOCATION: replace(21, "")
    - (D) OTHER INFORMATION: /note= "N is C or T"
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

ATGTANAANA ANGANTCNAA NGT

(2) INFORMATION FOR SEQ ID NO: 7:

```
(i) SEQUENCE CHARACTERISTICS:
          (A) LENGTH: 23 base pairs
          (B) TYPE: nucleic acid
          (C) STRANDEDNESS: single
          (D) TOPOLOGY: linear
    (ii) MOLECULE TYPE: DNA (genomic)
    (ix) FEATURE:
          (A) NAME/KEY: misc_difference
          (B) LOCATION: replace(6, "")
          (D) OTHER INFORMATION: /note= "N is T or C"
    (ix) FEATURE:
          (A) NAME/KEY: misc difference
          (B) LOCATION: replace(9, "")
          (D) OTHER INFORMATION: /note= "N is C or T"
    (ix) FEATURE:
          (A) NAME/KEY: misc difference
          (B) LOCATION: replace(12, "")
          (D) OTHER INFORMATION: /note= "N is C or T"
    (ix) FEATURE:
          (A) NAME/KEY: misc_difference
          (B) LOCATION: replace(15, "")
          (D) OTHER INFORMATION: /note= "N is C or T"
    (ix) FEATURE:
          (A) NAME/KEY: misc difference
          (B) LOCATION: replace(18, "")
          (D) OTHER INFORMATION: /note= "N is C or T"
    (ix) FEATURE:
          (A) NAME/KEY: misc_difference
          (B) LOCATION: replace(21, "")
          (D) OTHER INFORMATION: /note= "N is C or T"
    (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
                                                                         23
ATGTANAANA ANGANAGNAA NGT
(2) INFORMATION FOR SEQ ID NO: 8:
     (i) SEQUENCE CHARACTERISTICS:
          (A) LENGTH: 17 base pairs
          (B) TYPE: nucleic acid
          (C) STRANDEDNESS: single
          (D) TOPOLOGY: linear
```

(ii) MOLECULE TYPE: DNA (genomic)

## 37/8

	(ix)	FEATURE:  (A) NAME/KEY: misc_difference  (B) LOCATION: replace(3, "")  (D) OTHER INFORMATION: /note= "N is G or A or T or C"	
	(ix)	FEATURE:  (A) NAME/KEY: misc_difference  (B) LOCATION: replace(6, "")  (D) OTHER INFORMATION: /note= "N is G or A"	
	(ix)	FEATURE:  (A) NAME/KEY: misc_difference  (B) LOCATION: replace(9, "")  (D) OTHER INFORMATION: /note= "N is G or A"	
	(ix)	FEATURE:  (A) NAME/KEY: misc_difference  (B) LOCATION: replace(12, "")  (D) OTHER INFORMATION: /note= "N is G or A or T or C"	
	(ix)	FEATURE:  (A) NAME/KEY: misc_difference  (B) LOCATION: replace(15, "")  (D) OTHER INFORMATION: /note= "N is G or A or T or C"	
•	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO: 8:	
TANC	CNTC	NT GNCCNCC	17
(2)	INFO	RMATION FOR SEQ ID NO: 9:	
	(i)	SEQUENCE CHARACTERISTICS:  (A) LENGTH: 20 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
	(ii)	MOLECULE TYPE: DNA (genomic)	
	(ix)	FEATURE:  (A) NAME/KEY: misc_difference  (B) LOCATION: replace(3, "")  (D) OTHER INFORMATION: /note= "N is G or A or T or C"	
	(ix)	FEATURE:  (A) NAME/KEY: misc_difference  (B) LOCATION: replace(6, "")  (D) OTHER INFORMATION: /note= "N is G or A"	
	(ix)	FEATURE:  (A) NAME/KEY: misc_difference  (B) LOCATION: replace(9, "")  (D) OTHER INFORMATION: /note= "N is C or T"	

SUBSTITUTE SHEET (RULE 26)

WO 95/10618

37/9

- (ix) FEATURE:
  - (A) NAME/KEY: misc difference
  - (B) LOCATION: replace(12, "")
  - (D) OTHER INFORMATION: /note= "N is G or A"
- (ix) FEATURE:
  - (A) NAME/KEY: misc difference
  - (B) LOCATION: replace(18, "")
  - (D) OTHER INFORMATION: /note= "N is C or T"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

#### **GGNCCNAANT TNTACCANTG**

20

- (2) INFORMATION FOR SEQ ID NO: 10:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 17 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear
    - (ii) MOLECULE TYPE: DNA (genomic)
    - (ix) FEATURE:
      - (A) NAME/KEY: misc\_difference
        (B) LOCATION: replace(3, "")

      - (D) OTHER INFORMATION: /note= "N is T or C"
    - (ix) FEATURE:
      - (A) NAME/KEY: misc\_difference
      - (B) LOCATION: replace(6, "")
      - (D) OTHER INFORMATION: /note= "N is G or A or T or C"
    - (ix) FEATURE:
      - (A) NAME/KEY: misc\_difference
      - (B) LOCATION: replace(12, "")
      - (D) OTHER INFORMATION: /note= "N is G or A"
    - (ix) FEATURE:
      - (A) NAME/KEY: misc difference
      - (B) LOCATION: replace(15, "")
      - (D) OTHER INFORMATION: /note= "N is G or A"
    - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

TANCGNTGGC ANGANGT

17

(2) INFORMATION FOR SEQ ID NO: 11:

(1) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 17 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA (genomic)	
<pre>(ix) FEATURE:     (A) NAME/KEY: misc_difference     (B) LOCATION: replace(3, "")     (D) OTHER INFORMATION: /note= "N is T or C"</pre>	
<pre>(ix) FEATURE:     (A) NAME/KEY: misc_difference     (B) LOCATION: replace(6, "")     (D) OTHER INFORMATION: /note= "N is G or A"</pre>	
<pre>(ix) FEATURE:     (A) NAME/KEY: misc_difference     (B) LOCATION: replace(12, "")     (D) OTHER INFORMATION: /note= "N is G or A"</pre>	
<pre>(ix) FEATURE:     (A) NAME/KEY: misc_difference     (B) LOCATION: replace(15, "")     (D) OTHER INFORMATION: /note= "N is G or A"</pre>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:	
TANAGNTGGC ANGANGT	17
(2) INFORMATION FOR SEQ ID NO: 12:	
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 71 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
(ii) MOLECULE TYPE: DNA (genomic)	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:	
ATGTACAACA ACGACTCGAA CGTTCGCAGG GCGCAGAACG ATCATTTCCT TCTTGGCGGC	60
CACGACGGTT A	71

(2)	INFO	RMATION FOR SEQ ID NO: 13:	
	(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear	
	(ii)	MOLECULE TYPE: peptide	
	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO: 13:	
	Met 1	Tyr Asn Asn Asp Ser Asn Val Arg Arg Ala Gln Asn Asp His Phe 15	
	Leu	Leu Gly Gly His Asp Gly 20	
(2)	INFO	RMATION FOR SEQ ID NO: 14:	
	(i)	SEQUENCE CHARACTERISTICS:  (A) LENGTH: 160 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
	(11)	MOLECULE TYPE: DNA (genomic)	
	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO: 14:	
TGT	ACAA	CA ACGACTCGAA CGTTCGCAGG GCGCAGAACG ATCATTTCCT TCTTGGTGGA	60
ATG	ATGG	AT ATCGCATTCT GTGCGCGCCT GTTGTGTGGG AGAATTCGAC CGAACGGAAT	120
GTA	CTTG	CC CGTGCTGACC CAATGGTACA AATTCGGCCC	160
2)	INFO	RMATION FOR SEQ ID NO: 15:	
	(i)	SEQUENCE CHARACTERISTICS:  (A) LENGTH: 54 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear	
	(ii)	MOLECULE TYPE: peptide	
	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO: 15:	
	Met 1	Tyr Asn Asn Asp Ser Asn Val Arg Arg Ala Gln Asn Asp His Phe 15	

Leu Leu Gly Gly His Asp Gly Tyr Arg Ile Leu Cys Ala Pro Val Val 20 25 30

Trp Glu Asn Ser Thr Glu Arg Glu Leu Tyr Leu Pro Val Leu Thr Gln
35 40 45

Trp Tyr Lys Phe Gly Pro 50

#### (2) INFORMATION FOR SEQ ID NO: 16:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 238 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

TACAGGTGGC AGGAGGTGTT GTACACTGCT ATGTACCAGA ATGCGGCTTT CGGGAAACCG 60
ATTATCAAGG CAGCTTCCAT GTACGACAAC GACAGAAACG TTCGCGGCGC ACAGGATGAC 120
CACTTCCTTC TCGGCGGACA CGATGGATAT CGTATTTTGT GTGCACCTGT TGTGTGGGAG 180
AATACAACCA GTCGCGATCT GTACTTGCCT GTGCTGACCA GTGGTACAAA TTCGGCCC 238

#### (2) INFORMATION FOR SEQ ID NO: 17:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 79 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

Tyr Arg Trp Gln Glu Val Leu Tyr Thr Ala Met Tyr Gln Asn Ala Ala 1 10 15

Phe Gly Lys Pro Ile Ile Lys Ala Ala Ser Met Tyr Asp Asn Asp Arg 20 25 30

Asn Val Arg Gly Ala Gln Asp Asp His Phe Leu Leu Gly Gly His Asp 35 40 45

Gly Tyr Arg Ile Leu Cys Ala Pro Val Val Trp Glu Asn Thr Thr Ser 50 55 60

#### SUBSTITUTE SHEET (RULE 26)

WO 95/10618 PCT/EP94/03399

Arg Asp Leu Tyr Leu Pro Val Leu Thr Lys Trp Tyr Lys Phe Gly 65 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: GCTCTAGAGC ATGTTTTCAA CCCTTGCG 28 (2) INFORMATION FOR SEO ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: AGCTTGTTAA CATGTATCCA ACCCTCACCT TCGTGG 36 (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: ACAATTGTAC ATAGGTTGGG AGTGGAAGCA CCGC 34

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page					
B. IDENTIFICATION OF DEPOSIT	Further deposits are identified on an additional sheet				
Name of depositary institution					
The National Collections of Industrial	and Marine Bacteria Limited (NCIMB)				
Address of depositary institution (including postal code and country	)				
23 St. Machar Drive Aberdeen					
Scotland					
AB2 1RY					
United Kingdom					
Date of deposit 20 JUNE 1994	Accession Number NCIMB 40652				
C. ADDITIONAL INDICATIONS (leave blank if not applicable	ole) This information is continued on an additional sheet				
In respect of those designations in which a European patent is sought, and any other designated state having equivalent legislation, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC).  D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
E. SEPARATE FURNISHING OF INDICATIONS (leave	e blank if not applicable)				
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only	For International Bureau use only				
This sheet was received with the international application	This sheet was received by the International Bureau on:				
Authorized officer	Authorized officer				

Form PCT/RO/134 (July 1992)

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorgani on page, line	sm referred to in the description 24			
B. IDENTIFICATION OF DEPOSIT	Further deposits are identified on an additional sheet			
Name of depositary institution				
The National Collections of Industr	ial and Marine Bacteria Limited (NCIMB)			
Address of depositary institution (including postal code and c	country)			
23 St. Machar Drive Aberdeen				
Scotland				
AB2 1RY United Kingdom	·			
Date of deposit 20 JUNE 1994	Accession Number			
28 JUNE 1974	NCIMB 40653			
C. ADDITIONAL INDICATIONS (leave blank if not ap	plicable) This information is continued on an additional sheet			
other designated state having equivalent legislation, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC).  D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)				
E. SEPARATE FURNISHING OF INDICATIONS				
	onal Bureau later (specify the general nature of the indications e.g., "Accession			
o, Deposit y				
Correction Office was also				
For receiving Office use only  This sheet was received with the international application	For International Bureau use only  This sheet was received by the International Bureau on:			
Lust				
Authorized officer	Authorized officer			
m PCT/RO/134 (July 1992)				

# INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

B. IDENTIFICATION OF DEPOSIT    Name of depositary institution   Culture Collection of Algae and Protozoa (CCAP)	A. The indications made below relate to the microorganism relate on page, line	Terred to in the description
Culture Collection of Algae and Protozoa (CCAP)  Address of depositary institution (including postal code and country)  Dunstaffnage Marine Laboratory P.O. Box 3  Oben Argyll PA34 4AD Scotland United Kingdom  Date of deposit  CCAP 1373/1  C. ADDITIONAL INDICATIONS (leave blank if not applicable)  In respect of those designations in which a European patent is sought, and any other designated state having equivalent legislation, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC).  D. DESIGNATED STATES FOR WHICH INDICATIONS (leave blank if not applicable)  E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)  The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., 'Accession Number of Deposit')  This sheet was received with the international application  For receiving Office use only  This sheet was received by the International Bureau on:  Authorized officer	B. IDENTIFICATION OF DEPOSIT	Further deposits are identified on an additional sheet
Address of depositary institution (including postal code and country)  Dunstaffnage Marine Laboratory P.O. Box 3  Oban Argyll PA34 4AD Scotland United Kingdom  Date of deposit  C. ADDITIONAL INDICATIONS (tenve blank if not applicable)  In respect of those designations in which a European patent is sought, and any other designated state having equivalent legislation, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EFC).  D. DESIGNATED STATES FOR WHICH INDICATIONS (tenve blank if not applicable)  The indications listed below will be submitted to the International Buresu later (specify the general nature of the indications e.g., "Accession Number of Deposit")  This sheet was received with the international application Authorized officer  Authorized officer	Name of depositary institution	
Dunstaffnage Marine Laboratory P.O. Box 3 Oban Argyll PA34 4AD Scotland United Kingdom  Date of deposit    OCTOBER 1994   Accession Number   1373	Culture Collection of Algae and Protozo	oa (CCAP)
Date of deposit    Cadding   Pass   P	Address of depositary institution (including postal code and country)	)
Date of deposit    OCTOBER 1994	P.O. Box 3 Oban	
C. ADDITIONAL INDICATIONS (leave blank if not applicable)  This information is continued on an additional abeet  In respect of those designations in which a European patent is sought, and any other designated state having equivalent legislation, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC).  D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)  E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)  The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., 'Accession Number of Deposit')  This sheet was received with the international application  Authorized officer  Authorized officer		
In respect of those designations in which a European patent is sought, and any other designated state having equivalent legislation, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC).  D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)  E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)  The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")  This sheet was received with the international application  Authorized officer  Authorized officer	Date of deposit 11 OCTOBER 1994	Accession Number
other designated state having equivalent legislation, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC).  D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)  E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)  The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")  For receiving Office use only  This sheet was received by the International Bureau on:  Authorized officer	C. ADDITIONAL INDICATIONS (leave blank if not applicab	le) This information is continued on an additional sheet
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)  The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")  For receiving Office use only  This sheet was received with the international application  Authorized officer  Authorized officer	other designated state having equivalen microorganism will be made available un grant of the European patent or until t refused or withdrawn or is deemed to be sample to an expert nominated by the pe	t legislation, a sample of the deposited til the publication of the mention of the he date on which the application has been withdrawn, only by the issue of such a
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")  For receiving Office use only  This sheet was received with the international application  Authorized officer  Authorized officer	D. DESIGNATED STATES FOR WHICH INDICATION	NS ARE MADE (if the indications are not for all designated States)
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")  For receiving Office use only  This sheet was received with the international application  Authorized officer  Authorized officer	·	·
Number of Deposit*)  For receiving Office use only  This sheet was received with the international application  Authorized officer  Authorized officer	E. SEPARATE FURNISHING OF INDICATIONS (leave	e blank if not applicable)
This sheet was received with the international application  Authorized officer  Authorized officer  Authorized officer		Bureau later (specify the general nature of the indications e.g., "Accession
This sheet was received with the international application  Authorized officer  Authorized officer  Authorized officer		
		This sheet was received by the International Bureau on:
	Authorized officer  Form PCT/RO/134 (July 1992)	Authorized officer

#### **CLAIMS**

5

- 1. A method of preparing the enzyme  $\alpha$ -1,4-glucan lyase (GL) comprising isolating the enzyme from a fungally infected algae.
- 2. A method according to claim 1 wherein the enzyme is isolated and/or further purified using a gel that is not degraded by the enzyme.
- 3. A method according to claim 2 wherein the gel is based on dextrin or derivatives thereof, preferably a cyclodextrin, more preferably beta-cyclo-dextrin.
  - 4. A GL enzyme prepared by the method according to any one of claims 1 to 3.
- 5. An enzyme comprising the amino acid sequence SEQ. ID. No. 1. or SEQ. ID.No. 2, or any variant thereof.
  - 6. A nucleotide sequence coding for the enzyme  $\alpha$ -1,4-glucan lyase.
- 7. A nucleotide sequence according to claim 6 wherein the sequence is a DNA sequence.
  - 8. A nucleotide sequence according to claim 7 wherein the DNA sequence comprises a sequence that is the same as, or is complementary to, or has substantial homology with, or contains any suitable codon substitutions for any of those of, SEQ. ID. No. 3 or SEQ. ID. No. 4.
  - 9. A method of preparing the enzmye  $\alpha$ -1,4-glucan lyase comprising expressing the nucleotide sequence according to any one of claims 6 to 8.

25

WO 95/10618 PCT/EP94/03399

42

- 10. A method according to any one of the preceding claims wherein the algae is Gracilariopsis lemaneiformis.
- 11. The use of beta-cyclodextrin to purify an enzyme, preferably GL.

5

12. A nucleotide sequence wherein the DNA sequence comprises a sequence that is the same as, or is complementary to, or has substantial homology with, or contains any suitable codon substitutions for any of those of, SEQ. ID. No. 3 or SEQ. ID. No. 4.

10






Fig.1. Calcoflour White stainings revealing fungi in upper part and lower part of Gracilaria lemnaeformis. (108x and 294x).



Fig. 2. PAS / Anilinblue Black staining of Gracilaria lemnaeformis with fungi. The fungi have a significant higher content of carbohydrates.



Fig. 3. The micrograph shows longitudinal and grazing sections of two thin-walled fungal hypha (f) growing between thick walls (w) of algal cells. Note thylacoid membranes in the algal chloroplast (arrows).




Fig.4. The antisense detections with clone 2 probe (upper row) are restricted to the fungiillustrated by the Calcoflour White staining of the succeeding section (lower row). (46x and 108x).






Fig.5. Intense antisense detections with clone 2 probe are found over the fungi in Gracilaria lemnaeformis (294x).

F19.6.



F19.7.



#### FIGURE 8

MFSTLAFVAP SALGASTFVG AEVRSNVRIH SAFPAVHTAT RKTNRLNVSM TALSDKQTAT AGSTDNPDGI DYKTYDYVGV WGFSPLSNTN WFAAGSSTPG GITDWTATMN VNFDRIDNPS ITVQHPVQVQ VTSYNNNSYR VRFNPDGPIR DVTRGPILKQ QLDWIRTQEL SEGCDPGMTF TSEGFLTFET KDLSVIIYGN FKTRVTRKSD GKVIMENDEV GTASSGNKCR GLMFVDRLYG NAIASVNK<u>NF RNDAVKOEGF YGAGEVNCK</u>Y QDTYILERTG IAMTNYNYDN LNYNOWDLRP PHHDGALNPD YYIPMYYAAP WLIVNGCAGT SEQYSYGWFM DNVSOSYMNT GDTTWNSGOE DLAYMGAQYG PFDQHFVYGA GGGMECVVTA FSLLQGKEFE NQVLNKRSVM PPKYVFGFFQ GVFGTSSLLR AHMPAGENNI SVEEIVEGYQ NNNFPFEGLA VDVDMQDNLR VFTTKGEFWT ANRVGTGGDP NNRSVFEWAH DKGLVCOTNI TCFLRNDNEG ODYEVNOTLR ERQLYTKNDS LTGTDFGMTD DGPSDAYIGH LDYGGGVECD ALFPDWGRPD VAEWWGNNYK KLFSIGLDFV WQDMTVPAMM PHKIGDDINV KPDGNWPNAD DPSNGQYNWK TYHPQVLVTD MRYENHGREP <u>MVTORN</u>IHAY TLCESTRKEG IVENADTLTK FRRSYIISRG GYIGNQHFGG MWVGDNSTTS NYIQMMIANN INMNMSCLPL VGSDIGGFTS YDNENQRTPC TGDLMVRYVO AGCLLPWFRN HYDRWIESKO HGKDYQELYM YPNEMDTLRK FVEFRYRWOE VLYTAMYONA AFGKPIIKAA SMYNNDSNVR RAONDHFLLG GHDGYRILCA PVVWENSTER ELYLPVLTOW YKFGPDFDTK PLEGAMNGGD RIYNYPVPQS ESPIFVREGA ILPTRYTLNG ENKSLNTYTD EDPLVFEVFP LGNNRADGMC YLDDGGVTTN AEDNGKFSVV K<u>VAAEODGGT ETITFTNDCY EYVFGG</u>PFYV RVRGAQSPSN IHVSSGAGSQ DMKVSSATSR AALFNDGENG DFWVDOETDS LWLKLPNVVL PDAVITIT

FIGURE	9		
GL1	-	MFSTLAFVAPSALGASTFVGAEV-RSNVRIHSAFPAVHTATRKTNRLNVS -49	
GL2	-	MYPTLTFVAPSALGARTFTCVGIFRSHILIHSVVPAVRLAVRKSNRLNVS -50	
GL1	_	MTALSDKQTATAGSTDNPDGIDYKTYDYVGVWGFSPLSNTNWFAAGSSTP -99	
GL2	_	MSALFDKPTAVTGGKDNPDNINYTTYDYVPVWRFDPLSNTNWFAAGSSTP -100	)
GL1	-	GGITDWTATMNVNFDRIDNPSITVQHPVQVQVTSYNNNSYRVRFNPDGPI -149	}
GL2	-	GDIDDWTATMNVNFDRIDNPSFTLEKPVQVQVTSYKNNCFRVRFNPDGPI -150	)
GL1	_	RDVTRGPILKQQLDWIRTQELSEGCDPGMTFTSEGFLTFETKDLSVIIYG -199	,
GL2	-	RDVDRGPILQQQLNWIRKQEQSKGFDPKMGFTKEGFLKFETKDLNVIIYG -200	)
GL1	-	NFKTRVTRKSDGKVIMENDEVGTASSGNKCRGLMFVDRLYGNAIASVNKN -249	)
GL2	-	NFKTRVTRKRDGKGIMENNEVPAGSLGNKCRGLMFVDRLYGTAIASVNEN -250	)
GL1	-	FRNDAVKQEGFYGAGEVNCKYQDTYILERTGIAMTNYNYDNLNY -293	ţ
GL2	-	YRNDPDRKEGFYGAGEVNCEFWDSEQNRNKYILERTGIAMTNYNYDNYNY -300	)
GL1	-	NQWDLRPPHHDGALNPDYYIPMYYAAPWLIVNGCAGTS-EQYSYGWFMDN -342	;
GL2	-	NQSDLIAPGYPSDPNFYIPMYFAAPWVVVKGCSGNSDEQYSYGWFMDN -348	ļ
GL1	-	VSQSYMNTGDTTWNSGQEDLAYMGAQYGPFDQHFVYGAGGGMECVVTAFS -392	;
GL2	***	VSQTYMNTGGTSWNCGEENLAYMGAQCGPFDQHFVYGDGDGLEDVVQAFS -398	;
GL1	_	LLQGKEFENQVLNKRSVMPPKYVFGFFQGVFGTSSLLRAHMPAGENNISV -442	
GL2	_	LLQGKEFENQVLNKRAVMPPKYVFGYFQGVFGIASLLREQRPEGGNNISV -448	
GL1	-	EEIVEGYQNNNFPFEGLAVDVDMQDNLRVFTTKGEFWTANRVGTGGDPNN -492	
GL2	-	QEIVEGYQSNNFPLEGLAVDVDMQQDLRVFTTKIEFWTANKVGTGGDSNN -498	
GL1	-	RSVFEWAHDKGLVCQTNITCFLRNDNEGQDYEVNQTLRERQLYTKNDSLT -542	
GL2	-	KSVFEWAHDKGLVCQTNVTCFLRNDNGGADYEVNQTLREKGLYTKNDSLT -548	
GL1	-	GTDFGMTDDGPSDAYIGHLDYGGGVECDALFPDWGRPDVAEWWGNNYKKL -592	
GL2	-	NTNFGTTNDGPSDAYIGHLDYGGGGNCDALFPDWGRPGVAEWWGDNYSKL -598	
GL1	-	FSIGLDFVWQDMTVPAMMPHKIGDDINVKPDGNWPNADDPSNGQYNWKTY -642	
GL2	-	FKIGLDFVWQDMTVPAMMPHKVGDAVDTRSPYGWPNENDPSNGRYNWKSY -648	
GL1	-	HPQVLVTDMRYENHGREPMVTQRNIHAYTLCESTRKEGIVENADTLTKFR -692	
GL2	-	HPQVLVTDMRYENHGREPMFTQRNMHAYTLCESTRKEGIVANADTLTKFR -698	
GL1	-	RSYIISRGGYIGNQHFGGMWVGDNSTTSNYIQMMIANNINMNMSCLPLVG -742	
GL2	-	RSYIISRGGYIGNQHFGGMWVGDNSSSQRYLQMMIANIVNMNMSCLPLVG -748	
GL1	_	SDIGGFTSYDNENQRTPCTGDLMVRYVQAGCLLPWFRNHYDRWIESKDHG -792	
GL2		SDIGGFTSYDGRNVCPGDLMVRFVQAGCLLPWFRNHYGRLVEGKQEG -795	
GL1	-	KDYQELYMYPNEMDTLRKFVEFRYRWQEVLYTAMYQNAAFGKPIIKAASM -842	
21.9	_	* * * * * * * * * * * * * * * * * * *	

# FIGURE 9 continued

GL1	<ul> <li>YNNDSNVRRAQNDHFLLGGHDGYRILCAPVVWENSTERELYLPVLTQWYK -892</li> </ul>
GL2	: :: ::: :: ::::::::::::::::::::::::::
GLZ	- YDNDRNVRGAQDDHFLLGGHDGYRILCAPVVWENTTSRDLYLPVLTKWYK -895
GL1	- FGPDFDTKPLEGAMNGGDRIYNYPVPQSESPIFVREGAILPTRYTLNGEN -942
GL2	- FGPDYDTKRLDSALDGGQMIKNYSVPQSDSPIFVREGAILPTRYTLDGSN -945
GL1	- KSLNTYTDEDPLVFEVFPLGNNRADGMCYLDDGGVTTNAEDNGKFSVVKV -992
	**.**** :::::::::::::::::::::::::::::::
GL2	- KSMNTYTDKDPLVFEVFPLGNNRADGMCYLDDGGITTDAEDHGKFSVINV -995
GL1	- AAEQDGGTETITFTNDCYEYVFGGPFYVRVRGAQSPSNIHVSSGAGSQDM -104
	: ::::::::::::::::::::::::::::::::::::
GL2	- EALRKGVTTTIKFAYDTYQYVFDGPFYVRIRNLTTASKINVSSGAGEEDM -104
GL1	- KVSSATSRAALFNDGENGDFWVDQETDSLWLKLPNVVLPDAVITIT -1088
	.:: ::::: :: :: :: ::::::::::::::::
GL2	- TPTSANSRAALFSDGGVGEYWADNDTSSLWMKLPNLVLODAVITIT -1091




Figure 6 Microphotograph of a fungal hypha (f) growing between algal cell walls (w). Note grains of floridean starch (s) and thylakoids (arrows) in the algal cell. Bar =  $2 \mu m$ .